Document:

<PAGE>   1
                                                                    EXHIBIT 10.2

                          ADDITIONAL SERVICES AGREEMENT

         This Additional Services Agreement is entered into as of this 1st day
of January, 2000 by and between Biogen, Inc., through its offices located at 701
Green Valley Road, Suite 308, Greensboro, NC 27408 ("Biogen"), and Nova Factor,
Inc., with principal offices located at 1620 Century Center Parkway, Suite 109,
Memphis, TN 38134 ("Nova Factor").

         WHEREAS, Biogen has appointed Nova Factor as a preferred distributor of
Biogen's AVONEX(R) (Interferon beta - 1a) under the terms of a Distribution and
Services Agreement between the parties dated as of January 1, 2000 (the
"Distribution Agreement");

         WHEREAS, under the Distribution Agreement, Nova Factor has agreed to
provide reimbursement assistance and other customer services to end-users of
AVONEX(R) and to provide data reporting and other services to Biogen;

         WHEREAS, Biogen desires Nova Factor to perform certain additional
services for Biogen in connection with Biogen's customer services efforts
related to AVONEX(R) and Nova Factor is willing to provide such additional
services on the terms and conditions set forth in this Agreement;

         NOW THEREFORE, in consideration of the premises and mutual covenants
contained in this Agreement, the parties hereby agree as follows:

1.       DEFINITIONS.

1.1      "Access Program" shall mean the financial assistance program available
         to certain end-users of Product funded by Biogen and administered for
         Biogen by a third party administrator designated by Biogen.

1.2      "Adverse Event" shall have the meaning set forth in 21 CFR 600.80.

1.3      "Affiliates" shall mean, with respect to a given party, any
         corporation, firm, partnership or other entity which directly or
         indirectly controls or is controlled by or is under common control with
         such party. For purposes of this Section 1.3, "control" shall mean
         direct or indirect ownership of greater than fifty percent (50%) of the
         equity having the power to vote on or direct the affairs of the entity.

1.4      "Alliance Kit" shall mean a plastic ziplock bag containing five
         syringes, five MicroPins(R) and five needles intended for use with
         Product.

                                       1
<PAGE>   2

1.5      "Alliance Program" shall mean a program established by Biogen to
         provide educational information and materials to persons using Product.

1.6      "Alliance Program Participant" shall mean an end-user of Product who
         has enrolled in the Alliance Program.

1.7      "Emergency Component Shipment" shall have the meaning set forth in
         Section 2.2(d).

1.8      "FDA" shall mean the United States Food and Drug Administration.

1.9      "Hotline Customer" shall mean an end-user who is referred to Nova
         Factor via the Reimbursement Hotline.

1.10     "Incentive Plan" shall have the meaning set forth in Section 10.2.

1.11     "IND" shall mean an Investigational New Drug application filed with the
         FDA.

1.12     "Investigator" shall mean a physician who, with the consent of Biogen,
         has filed and will be conducting research under an
         investigator-sponsored IND for investigational use of Product.

1.13     "Outcome Call" shall have the meaning set forth in Section 8.1 of this
         Agreement.

1.14     "Program Fee" shall have the meaning set forth in Section 3.4.

1.15     "Program Participant" shall have the meaning set forth in Section 3.2.

1.16     *

1.17     *

1.18     "Reimbursement Hotline" shall mean telephone access to reimbursement
         specialists at Nova Factor who are trained to answer or find answers to
         reimbursement questions and problems related to Product which such
         access is available through a telephone line at Nova Factor dedicated
         to calls transferred from Biogen, all as more fully described in
         Section 7.

1.19     *

1.20     "Replacement Components" shall mean diluent, syringes, MicroPins(R) and
         needles intended for use with Product.

1.21     "Services" shall mean the services to be provided by Nova Factor under
         this Agreement.

1.22     "Service Fee Schedule" shall mean the schedule of service fees attached
         to this Agreement as Schedule A.

* - Confidential Treatment Requested

                                       2
<PAGE>   3

1.23     "Service Report" shall have the meaning set forth in Section 10.2.

1.24     "SOPs" shall mean the written standard operating procedures,
         specifications and instructions approved by both parties, as the same
         may be amended from time to time by the parties.

1.25     "Specifications" shall mean the specifications for Replacement
         Components provided to Nova Factor by Biogen, as updated by Biogen from
         time to time.

1.26     "Training Provider" shall mean Interim Healthcare, Inc. or such other
         company as Biogen shall engage to provide Product administration
         training services, and as to whose appointment Biogen shall notify Nova
         Factor in writing at least 14 days in advance of the engagement.

1.27     "Triaged Customer" shall mean an end-user (other than a Hotline
         Customer) who is referred to Nova Factor under the * or referred to
         Nova Factor by a Biogen customer support specialist, as contemplated
         under Distribution Agreement, but who decides not to use Nova Factor's
         home delivery services for delivery of Product.

1.28     "Hours" In calculating time periods in hours or days throughout this
         Agreement, except for purposes of Schedule C, weekends and holidays
         shall be excluded from the calculation.

2.       REPLACEMENT AND RETURN SERVICES.

2.1      Replacement Product.

         (a) Obligation. From time to time users of Product and physicians who
         prescribe Product will require replacement Product. Nova Factor agrees
         to act as a supplier of replacement Product for Biogen. Upon receipt of
         each authorization from a Biogen customer support specialist to send
         replacement Product to an end-user of Product or to a physician who has
         purchased Product, Nova Factor shall supply replacement Product from
         its inventory to the end-user at the end-user's home, other residence,
         office or similar location, as designated by the end-user, or to the
         physician at the physician's office, whether or not such person is a
         customer of Nova Factor.

         (b) Authorization. Authorization from Biogen's customer support
         specialist for Nova Factor to supply replacement Product shall be in
         the form of the transfer of the telephone call from the end-user or
         physician on Biogen's customer support line to Nova Factor followed by
         same-day written confirmation from the Biogen customer support
         specialist that replacement Product may be sent, such written
         confirmation to specify the quantity of replacement Product to be sent
         and to be in a form mutually agreeable to the parties.

* - Confidential Treatment Requested

                                       3
<PAGE>   4

         (c) Shipment. Nova Factor shall supply replacement Product in one or
         more single dose packs or in the full package of four dose packs, as
         authorized by Biogen's customer support specialist. In no event shall
         Nova Factor open or alter the packaging of single dose packs of
         Product. Nova Factor shall package Product for shipment in insulated
         shipping units in accordance with the applicable SOP. Nova Factor shall
         ship replacement Product via Federal Express standard overnight
         delivery service or another mutually agreed to overnight carrier for
         delivery within twenty-four (24) hours of receipt of authorization from
         Biogen and notification to the patient, provided that Nova Factor has
         received a copy of the applicable prescription form. Nova Factor shall
         use reasonable efforts to obtain the prescription form for an end-user,
         as necessary, and to notify the end-user about the planned shipment in
         each case within twenty-four (24) hours of receipt of authorization
         from Biogen to ship replacement Product to such end-user. Nova Factor
         shall notify the appropriate Biogen customer support specialist in the
         event Nova Factor has not received the prescription form for an
         end-user within forty-eight (48) hours of receipt of authorization from
         Biogen.

2.2      Replacement Components.

         (a) Obligation. In addition to the Product replacement services
         specified under Section 2.1, Nova Factor shall, under the terms of this
         Agreement, act as a supplier of Replacement Components to end-users of
         Product (whether or not the end-users are Nova Factor customers) who
         have requested Replacement Components and whose requests have been
         approved by a Biogen customer support specialist.

         (b) Authorization. Approval from a Biogen customer support specialist
         for Nova Factor to supply Replacement Components shall be in the form
         of the transfer of the telephone call from the end-user on Biogen's
         customer support line to Nova Factor followed by same-day written
         confirmation from the Biogen customer support specialist. Upon receipt
         of a request from an end-user for Replacement Components, Nova Factor
         shall, using a qualified Nova Factor pharmacist, determine whether the
         supply of Replacement Components under the circumstances set forth by
         the end-user is appropriate and allowable, without a prescription,
         under applicable law.

         (c) Supply. If Nova Factor determines that the supply of Replacement
         Components is appropriate and allowable, without a prescription, under
         applicable law, Nova Factor shall supply the approved quantity and type
         of Replacement Components from a consignment inventory of Replacement
         Components provided by Biogen or from such other supply as Biogen shall
         approve and that is provided at Biogen's cost. Nova Factor shall send
         Replacement Components to an end-user at the end-user's home, other
         residence, office or similar location, as designated by the end-user.
         In the event Nova Factor determines that a prescription is required for
         the supply of Replacement Components to an end-user, Nova Factor shall
         use reasonable efforts to obtain the prescription from the end-user's
         physician within twenty-four (24) hours of the request. If Nova Factor,
         having used reasonable efforts, is unable to obtain a prescription from
         the

                                       4
<PAGE>   5

         end-user's physician within five (5) business days of receipt of the
         request for Replacement Components or if Nova Factor otherwise
         determines that the supply of Replacement Components to an end-user is
         not appropriate, Nova Factor shall notify a Biogen customer support
         specialist.

         (d) Shipment. Nova Factor shall ship Replacement Components to
         end-users via first-class mail unless the end-user requires an
         emergency supply in which case Nova Factor shall ship the Replacement
         Components via Federal Express standard overnight delivery service or
         another mutually agreed to overnight carrier (an "Emergency Component
         Shipment"). Nova Factor shall ship Replacement Components within
         twenty-four (24) hours of receipt of the request, unless Nova Factor
         determines that a prescription is required in which case Nova Factor
         shall ship Replacement Components within twenty-four (24) hours of
         receipt of the applicable prescription. Nova Factor shall package
         Replacement Components in accordance with industry standards, and shall
         include in the package a Nova Factor pharmacy label. If Replacement
         Components are not received by the intended recipient, Nova Factor
         shall use reasonable efforts to track and retrieve the missing
         shipment.

         (e) Quality Assurance. Unless Biogen otherwise approves, Nova Factor
         shall, in fulfilling its supply obligation under this Section 2, use
         only Replacement Components from the inventory that has been provided
         by Biogen or from an inventory otherwise approved by Biogen. Nova
         Factor shall handle and store all Replacement Components in accordance
         with applicable SOPs. Nova Factor shall ensure for each shipment of
         Replacement Components to an end-user that a registered pharmacist or
         pharmacy technician acting under the direct supervision of a registered
         pharmacist has verified that the Replacement Components being shipped
         are the Replacement Components that were requested and authorized.

2.3      Other Suppliers. Biogen reserves the right to appoint other suppliers
         of replacement Product and Replacement Components.

2.4      Cooperation. At Biogen's request, Nova Factor shall cooperate with
         Biogen in investigating the need for replacement Product and
         Replacement Components.

3.       ACCESS PROGRAM SUPPLY SERVICES.

3.1      Service. In addition to the other services to be provided by Nova
         Factor under this Agreement, Nova Factor shall act as a supplier of
         Product to participants in Biogen's Access Program.

3.2      Enrollment and Contact. Biogen shall have sole responsibility for
         enrolling participants in the Access Program. Upon enrollment by Biogen
         of a participant in the Access Program (each a "Program Participant"),
         one of Biogen's customer support specialists or a representative of
         Biogen's Access Program administrator shall notify Nova Factor in

                                       5
<PAGE>   6

         writing of the name, address and telephone number of the Program
         Participant and the amount of his or her spend-down, if any. Nova
         Factor shall obtain a copy of the applicable prescription form for the
         Program Participant. Within twenty-four (24) hours of receipt of notice
         under the preceding sentence, Nova Factor shall contact the Program
         Participant to obtain an order for Product. If the Program Participant
         has a spend-down component as part of the Access Program, the Program
         Participant may purchase the spend-down portion from Nova Factor or
         from another source. If the spend-down portion is purchased from Nova
         Factor, Nova Factor shall report on a monthly basis and either remit or
         credit against fees owed to it by Biogen the proceeds from the sale to
         Biogen. If the Program Participant purchases the spend-down portion
         from another source, Nova Factor shall obtain proof of purchase for the
         spend-down portion prior to shipping Product to the Program Participant
         under this Agreement.

3.3      Supply. Nova Factor shall supply Product to Program Participants from
         Nova Factor's inventory and shall deliver Product to the office of the
         Program Participant's physician within forty-eight (48) hours of
         receipt of each order. If the Program Participant requests delivery of
         Product to a location other than his or her physician's office, or if
         the physician refuses to accept delivery of the Product, Nova Factor
         shall notify Biogen, and Biogen will work with the Program Participant
         to determine an alternate shipping destination. Upon determination of
         an alternate shipping location, Biogen shall notify Nova Factor in
         writing of the address to which Product is to be shipped for the
         Program Participant, and Nova Factor shall then ship the Product in
         accordance with this Section. * Nova Factor shall package Product for
         shipment in insulated shipping units in accordance with the applicable
         SOP. Nova Factor shall ship Product to Program Participants via Federal
         Express standard overnight delivery services or another mutually agreed
         to overnight courier.

3.4      Participant Shipment Fees. As a condition to participation in the
         Access Program, Program Participants will agree to pay a shipment fee
         of * for each shipment of Product (other than the spend-down portion)
         after the initial shipment (the "Program Fee"). Nova Factor shall bill
         each Program Participant for the Program Fee, and shall send a
         follow-up reminder letter following the third shipment of Product if
         the Program Participant has not paid the Program Fee. Nova Factor shall
         apply the Program Fees collected for any month against the amount of
         the Access Program shipment fees owed by Biogen for such month under
         the Service Fee Schedule. Nova Factor shall not bill Program
         Participants for Product other than for the spend-down portion and for
         the amount of the Program Fees. Except to the extent expressly set
         forth in this paragraph, Nova Factor shall not be responsible for
         collecting Program Fees from Program Participants.

3.5      Follow-up; Change in Status. Nova Factor shall, to the extent
         consistent with applicable federal and state pharmacy laws, contact
         each Program Participant approximately one week before the Program
         Participant's supply of Product, assuming proper administration, will
         be depleted to determine if the person needs a new supply of Product.
         During each follow-up telephone call to a Program Participant under
         this Section 3.5, Nova Factor shall confirm that the Program
         Participant's insurance status or financial condition has not changed.
         If the Program Participant's insurance status or financial condition
         has changed, Nova Factor shall immediately notify Biogen or Biogen's
         third party Access Program

* - Confidential Treatment Requested

                                       6
<PAGE>   7

         administrator. Nova Factor shall have no obligation to verify
         information received from a Program Participant as to insurance status.
         Nova Factor shall not ship Product to a Program Participant under this
         Section after Nova Factor receives written notice from Biogen or
         Biogen's third party Access Program administrator that the Program
         Participant is no longer eligible to participate in the Access Program.

3.6      Progress Checks. To the extent allowable under applicable law, Nova
         Factor's customer service representatives shall call each new Program
         Participant one to three weeks after such person has received an
         initial shipment of Product under this Section to check on the person's
         progress. In checking on a Program Participant's progress, Nova Factor
         shall use a script and checklist mutually agreeable to the parties. At
         Biogen's request, Nova Factor shall, during its telephone conversations
         with Program Participants, conduct additional clinical efficacy and
         customer satisfaction surveys provided by Biogen and report the
         resulting information to Biogen in a manner consistent with any
         applicable confidentiality restrictions. The parties shall negotiate,
         in advance, the fee for each additional survey initiated by Biogen.

4.       ALLIANCE PROGRAM.

4.1      Supply of Alliance Kits. As further additional services under this
         Agreement, Nova Factor shall supply one Alliance Kit to each Alliance
         Program Participant identified by Biogen. Nova Factor shall use its
         best efforts not to send more than one Alliance Kit to each Alliance
         Program Participant, and shall notify a Biogen customer support
         specialist promptly in the event an Alliance Program Participant
         submits more than one voucher. Nova Factor shall not ship Alliance Kits
         to any Alliance Program Participant in any state in which a
         prescription for any of the Replacement Components contained in the
         Alliance Kits is required without having first obtained the necessary
         prescription. In the event Nova Factor determines that a prescription
         is required to supply an Alliance Kit to an Alliance Program
         Participant, Nova Factor shall use reasonable efforts to obtain a
         prescription from the end-user's physician within twenty-four (24)
         hours of receipt of identification by Biogen. If Nova Factor, having
         used reasonable efforts, is unable to obtain a prescription from an
         end-user's physician within five (5) business days of receipt of
         identification by Biogen, Nova Factor shall notify a Biogen customer
         support specialist.

4.2      Delivery. Nova Factor shall ship Alliance Kits within two (2) business
         days of receipt of identification by Biogen, unless Nova Factor
         determines that a prescription is required in which case Nova Factor
         shall ship Alliance Kits within two (2) business days of receipt of the
         applicable prescription. Nova Factor shall send Alliance Kits via first
         class mail, unless otherwise agreed by the parties. Nova Factor shall
         package Alliance Kits in accordance with industry standards, and shall
         include on the Alliance Kit a Nova Factor pharmacy label.

                                       7
<PAGE>   8

4.3      Components.

         (a) Source. Unless Biogen otherwise specifies, Nova Factor shall use
         Replacement Components in the Alliance Kits from the inventory supplied
         by Biogen.

         (b) Quality Assurance. For each shipment of an Alliance Kit to an
         end-user, Nova Factor shall ensure that a registered pharmacist or a
         pharmacy technician acting under the direct supervision of a registered
         pharmacist has verified that the Replacement Components contained in
         the Alliance Kit are as specified in this Agreement.

5.       SUPPLY OF PRODUCT FOR PHYSICIAN INVESTIGATIVE USE.

5.1      Service. As further additional services under this Agreement, Nova
         Factor shall, upon receipt of written authorization from Biogen, supply
         Product from Nova Factor's inventory to Investigators. Nova Factor
         shall package Product for shipment in insulated shipping units in
         accordance with the applicable SOP. Nova Factor shall ship Product to
         the location specified by the Investigator via Federal Express standard
         overnight delivery service or another mutually agreed to overnight
         courier for delivery within twenty-four (24) hours of receipt of the
         applicable authorization from Biogen. If the Investigator requests
         delivery of the Product to an end-user's home, Nova Factor shall obtain
         the necessary prescription from the physician. Product shall be
         supplied to Investigators under this Section at no cost to the
         Investigator.

5.2      Quantities. For the initial shipment of Product to an Investigator
         under this Section, Nova Factor shall deliver one package of Product (a
         one month's supply). For the next shipment to the Investigator, Nova
         Factor shall deliver two (2) packages of Product (a two (2) months'
         supply). For the final order of Product to an Investigator under a
         Biogen authorization, Nova Factor shall deliver three (3) packages of
         Product (a three (3) months' supply). Nova Factor shall not deliver
         more than a total of six (6) packages (a six months' supply) of Product
         to any Investigator without further authorization from Biogen.
         Notwithstanding anything herein to the contrary, in no event shall Nova
         Factor ship Product to any Investigator in a quantity more than the
         Investigator ordered or otherwise specified or in a quantity more than
         Biogen authorized or otherwise approved.

6.       *

7.       REIMBURSEMENT HOTLINE.

7.1      Hotline Services. As additional services under this Agreement, Nova
         Factor shall operate a Reimbursement Hotline through which end-users,
         physicians, nurses, pharmacies,

* - Confidential Treatment Requested

                                       8
<PAGE>   9

         payors, providers and others referred to Nova Factor by Biogen's
         customer support specialists will be able to obtain assistance in
         answering reimbursement-related questions and resolving
         reimbursement-related issues and problems. Nova Factor shall make the
         Reimbursement Hotline accessible as one of the connection options
         available through the Nova Factor telephone line dedicated to calls
         transferred from Biogen's customer support specialists. Services to be
         provided by Nova Factor as part of the Reimbursement Hotline shall
         include, but shall not be limited to, using reasonable efforts * If an
         end-user or other person referred to Nova Factor on the Reimbursement
         Hotline has any questions related to Medicare coverage for Product,
         Nova Factor shall, unless otherwise specified by Biogen, transfer the
         person to the third party service provider designated by Biogen to
         provide further assistance on Medicare issues.

7.2      Delivery Options. In presenting the delivery options available to an
         end-user referred to Nova Factor via the Reimbursement Hotline, Nova
         Factor shall follow a script which accurately describes all potential
         methods of delivery available to the end-user and which is in a form
         mutually agreeable to Nova Factor and Biogen. If the end-user decides
         not to use Nova Factor's home delivery services for delivery of
         Product, Nova Factor shall use reasonable efforts to obtain the name,
         telephone number and fax number of the desired dispensing pharmacy, and
         shall provide to the dispensing pharmacy, by telephone or fax, all of
         the information in Nova Factor's possession regarding the end-user.

7.3      Staffing. Nova Factor shall use qualified and properly trained
         reimbursement specialists to answer calls on the Reimbursement Hotline.
         The number of reimbursement specialists made available by Nova Factor
         to answer calls on the Reimbursement Hotline shall be determined by the
         volume of calls, and shall be that number which is sufficient to ensure
         a high level of customer service and satisfaction. The parties
         acknowledge that a "high level of customer service and satisfaction"
         for purposes of the preceding sentence shall mean the answering of
         eight-five percent (85%) of telephone calls within thirty (30) seconds.
         If Biogen believes that the number of reimbursement specialists made
         available by Nova Factor to answer calls on the Reimbursement Hotline
         is not sufficient to ensure a high level of customer service and
         satisfaction, Biogen shall notify Nova Factor and the parties shall
         meet to determine what mutually agreeable corrective actions Nova
         Factor shall take.

7.4      Direct Delivery Customers. Nothing in this Agreement or in the
         operation of the Reimbursement Hotline shall be deemed to limit in any
         way the obligation of Nova Factor to provide reimbursement-related
         services under the terms of Section 5 of the Distribution Agreement to
         those end-users who order Product from Nova Factor. Services provided
         by Nova Factor to end-users under Section 5 of the Distribution
         Agreement will not be considered Reimbursement Hotline services for
         purposes of Section 7 of this Agreement.

7.5      Customer Satisfaction Survey. At Biogen's request from time to time,
         Nova Factor shall, at no additional cost to Biogen, send customer
         satisfaction surveys to Hotline Customers in a form mutually agreed
         upon by the parties. The completed surveys shall be sent to Biogen.

* - Confidential Treatment Requested

                                       9
<PAGE>   10

7.6      Reliance on Payor Information. Nova Factor shall have no liability for
         relying upon information provided by third party payors concerning
         coverage in the event that such information shall subsequently prove to
         be incorrect, and Nova Factor may include a disclaimer to that effect
         in any communication with end-users or others regarding coverage by
         third party payors.

7.7      Information to Biogen. At Biogen's request, Nova Factor shall provide
         to Biogen information regarding reimbursement policies for Product
         generated by Nova Factor in the course of providing Services under this
         Agreement.

8.       *

9.       DATA AND REPORTS.

9.1      Data. Nova Factor shall maintain the information specified in Schedule
         B related to the Services in a Biogen-specific database (the
         "Database") (which may be the same database maintained under the
         Distribution Agreement).

9.2      Reports. Nova Factor shall generate and furnish to Biogen at the end of
         each month reports from the Database as specified in Schedule B which
         such reports shall include a service report, specifying the type and
         quantity of Services performed in a format mutually agreeable to the
         parties (the "Service Report"). At Biogen's request, Nova Factor will
         deliver the reports specified under this Section electronically through
         a reasonably secure internet connection in a format mutually approved
         by the parties.

9.3      Other Information. Nova Factor shall furnish to Biogen such additional
         information related to Services as Biogen may from time to time
         reasonably request to the extent generating such information will not
         result in a material increase in the costs incurred by Nova Factor in
         performing Services under this Agreement.

9.4      Audits. During the term of this Agreement and for a period of three (3)
         years after termination or expiration of this Agreement, Nova Factor
         shall maintain true and accurate records of the Services provided by
         Nova Factor under this Agreement in sufficient detail to enable Biogen
         to verify the amounts payable to Nova Factor under this Agreement. Nova
         Factor shall permit Biogen, during the term of this Agreement and for a
         period of three (3) years after termination or expiration of this
         Agreement, to examine periodically, but not more than once per year,
         during regular business hours, the books, ledgers, and records of Nova
         Factor for any year for the purpose of and to the extent necessary to
         verify the information provided by Nova Factor under this Agreement.
         The cost of such

* - Confidential Treatment Requested

                                       10
<PAGE>   11

         examination shall be borne by Biogen unless it shall be established by
         Biogen that, as a result of an error in information provided by Nova
         Factor, there was a miscalculation in the Service Fees or incentive
         payments for any quarter resulting in an over payment by Biogen of more
         than $10,000; provided that in no event shall audit costs borne by Nova
         Factor exceed $10,000 per audit.

10.      PAYMENT.

10.1     Service Fees. In consideration of the Services rendered by Nova Factor
         to Biogen under this Agreement, Biogen shall pay Nova Factor in
         accordance with the Service Fee Schedule attached to this Agreement as
         Schedule A.

10.2     *

10.3     Invoices. Nova Factor shall invoice Biogen at the end of each month for
         amounts due hereunder with respect to Services shown on the Service
         Report for such month and for any incentives earned under the Incentive
         Plan. The invoice shall be accompanied by data necessary to support the
         amount of incentive payments being sought by Nova Factor under the
         Incentive Plan. All amounts due hereunder shall be payable by check to
         Nova Factor in United States funds. Payment by Biogen shall be due
         within thirty (30) days from the date of the invoice.

10.4     Product Credit. Within thirty (30) days of receipt of the Service
         Report for any month, Biogen shall issue to Nova Factor a credit memo
         in an amount equal to the quantity of Product shipped during the month
         from Nova Factor's inventory under the terms of Sections 2.1, 3.1 and
         5.1 of this Agreement multiplied by the then current purchase price for
         Product *. Nova Factor may apply credits given under this Section
         against purchases of Product under the Distribution Agreement. Credits
         may not be assigned or transferred by Nova Factor to a third party, and
         no cash payments shall be made on account of any credit, except where
         Nova Factor has credit due on the termination of the Distribution
         Agreement. Nova Factor shall not unilaterally apply any credit against
         or make any deductions from payment due to Biogen under the
         Distribution Agreement without prior written notice to and approval of
         Biogen. Credits shall be applied under the Distribution Agreement on a
         first-in, first-out basis.

10.5     Other Costs and Expenses. Except as otherwise set forth herein, Nova
         Factor shall be responsible for all costs and expenses associated with
         fulfilling its obligations and performing Services under this
         Agreement. In no event shall Nova Factor charge an end-user, insurance
         provider or any other third party for any Services provided under this
         Agreement.

* - Confidential Treatment Requested

                                       11
<PAGE>   12

10.6     Payment Due; Late Fee. Biogen shall pay interest on a per diem basis on
         any amounts past due at an annualized rate of one and one-half percent
         (1 1/2%) over the prime rate then in effect at Fleet Bank, Boston,
         Massachusetts.

11.      TERM; TERMINATION.

11.1     Term. This Agreement shall become effective as of the date hereof and,
         unless earlier terminated in accordance with this Section, shall
         continue in effect for an initial term of three (3) years from the
         effective date. The parties may extend this Agreement by mutual written
         agreement.

11.2     Termination of Portion of Services. Biogen may terminate any portion of
         the Services at any time * written notice to Nova Factor without
         terminating the entire Agreement.

11.3     Voluntary Termination. Either party may terminate this Agreement for
         any reason, at any time, upon ninety (90) days' prior written notice to
         the other party.

11.4     Termination for Breach. Either party may terminate this Agreement (i)
         for a material breach by the other party upon thirty (30) days' prior
         written notice unless the breaching party cures the breach within such
         thirty (30) day period or (ii) in the event of any proceedings,
         voluntary or involuntary, in bankruptcy or insolvency, by or against
         the other party, or the appointment with or without the other parties'
         consent of a receiver for such party.

11.5     Transition. Upon receipt or delivery of a termination notice by Nova
         Factor with respect to all or any part of the Services or ninety (90)
         days prior to expiration of this Agreement at the end of the term, as
         applicable, the parties shall begin transition of the Services (or any
         part thereof being terminated) to a party to be designated by Biogen.
         After receipt of the termination notice with respect to all or any part
         of the Services, and during the period thereafter ending six (6) months
         after termination, Nova Factor shall use reasonable efforts to
         cooperate with Biogen in ensuring the smooth transition of the Services
         (or any part thereof being terminated), provided that after termination
         of this Agreement, Biogen shall upon receipt of Nova Factor's invoice
         reimburse Nova Factor for its reasonable expenses associated with such
         cooperation.

11.6     Transfer of Database and Files. Upon termination, Nova Factor shall
         transfer to Biogen a copy of the Database and files related to
         reimbursement policies applicable to Product, provided that if
         applicable patient confidentiality laws prohibit transfer of an
         end-user's name, Nova Factor shall transfer the Database using customer
         numbers, instead of names.

* - Confidential Treatment Requested

                                       12
<PAGE>   13

11.7     Return of Inventory. Within ten (10) days of termination of the
         Agreement, Nova Factor shall at Biogen's cost return to Biogen all
         Replacement Components and Alliance Kits then held in consignment
         inventory at Nova Factor.

11.8     Survival. Sections 11.5, 11.8, 12.12, 13.4, 14.1, 15, 16 and 20.7 shall
         survive termination or expiration of this Agreement.

12.      REPRESENTATIONS, WARRANTIES AND COVENANTS OF NOVA FACTOR.

12.1     Judgment under Pharmacy Laws. Nova Factor understands that Biogen's
         approval and transfer to Nova Factor of a request for Replacement
         Components or the submission of a voucher by an Alliance Program
         Participant shall not be deemed to replace, in whole or in part, the
         exercise by the Nova Factor pharmacist of his or her judgment under
         applicable pharmacy law as to whether the shipment of Replacement
         Components or Alliance Kits is permissible under applicable pharmacy
         laws.

12.2     Adverse Event Reporting. Nova Factor shall record and promptly report
         to Biogen any Adverse Events which come to the attention of Nova Factor
         in the performance of Services in accordance with the relevant SOP
         provided by Biogen.

12.3     Limitation on Promotional Activities. Nova Factor shall not engage in
         any promotional activities with respect to Product or the *, the Access
         Program or the Reimbursement Hotline, other than the distribution of
         literature approved by Biogen and other activities expressly authorized
         by Biogen. Nova Factor shall not use any promotional materials which
         refer to Product, the *, the Access Program or the Reimbursement
         Hotline unless such promotional materials have been approved in writing
         in advance by Biogen. Any promotional literature or verbal
         representations describing Nova Factor's role in the *, the Access
         Program or the Reimbursement Hotline shall be approved in advance in
         writing by Biogen.

12.4     Compliance with Law and Professional Standards. In performing its
         obligations under this Agreement, Nova Factor shall comply with all
         applicable laws and regulations, including but not limited to, federal
         and state pharmacy laws, laws relating to the disposal of
         pharmaceutical products and hazardous wastes, to the extent disposal of
         Product, Replacement Components and Alliance Kits is Nova Factor's
         responsibility under this Agreement, and all applicable professional
         and industry standards and good business practices.

12.5     Quality of Team. Nova Factor shall use a dedicated, well-trained,
         knowledgeable team of employees to handle Product and to perform the
         Services to be performed by Nova Factor under this Agreement. Subject
         to applicable laws, Biogen shall have the right to have an employee
         monitor from time to time Nova Factor's responses during telephone
         calls made

* - Confidential Treatment Requested

                                       13
<PAGE>   14

         in connection with Services. Nova Factor shall cooperate with Biogen to
         enable such monitoring activities. The end-user shall be notified at
         the beginning of a call to be monitored that monitoring for quality
         assurance purposes is to occur, each such notification to be in
         accordance with a script mutually agreeable to the parties.

12.6     Actions. Nova Factor shall not take any action which would materially
         adversely affect its standing or that of Biogen in the industry or with
         respect to Product customer base or which would undermine the image of
         Product.

12.7     Quality Reviews. Nova Factor shall periodically, but not less
         frequently than once per year, perform written quality reviews of Nova
         Factor's performance in fulfilling its obligations under this
         Agreement, and shall provide Biogen with copies of such reviews. Nova
         Factor shall administer a validation checklist to each employee
         performing Services upon completion of such employee's initial training
         and annually thereafter, and shall provide Biogen with copies of such
         checklists.

12.8     Licenses. Nova Factor represents that it now has and shall maintain in
         full force during the term of this Agreement all federal and state
         pharmacy, wholesaler and other licenses or approvals required by Nova
         Factor to fulfill its obligations under this Agreement, and except that
         Nova Factor shall not be required to maintain its licenses in any state
         which amends its laws and regulations to require an in-state pharmacy
         presence as a requirement for licensing if the new requirement would
         materially increase the costs incurred by Nova Factor in performing its
         obligations under this Agreement. Nova Factor shall provide Biogen with
         notice of any communications with pharmacy licensing boards which
         relate to potential problems with facilities, operations or procedures
         used by Nova Factor in performing Services, including notices of
         inquiries, investigations or inspections and resulting findings.

12.9     Use of Trademarks. Nova Factor shall not use the trademarks or
         tradenames of Biogen except to the extent contained in Product
         literature provided by Biogen and on Product labels or as otherwise
         approved by Biogen.

12.10    Authority. Nova Factor represents that it has the authority to enter
         into this Agreement and that its execution of this Agreement and its
         performance of its obligations hereunder will not conflict with and is
         not prohibited by any other agreement to which Nova Factor is a party.

12.11    Limitation on Liability. In no event shall Nova Factor be liable for
         loss of profit or any other incidental or consequential damages of
         Biogen.

12.12    End-User Lists. In no event shall Nova Factor use the lists of
         end-users generated in the course of Services except for purposes of
         performing Services for Biogen under this Agreement except as otherwise
         approved by Biogen. Nova Factor shall not make its end-user list or any
         portion thereof available to any third party.

                                       14
<PAGE>   15

13.      REPRESENTATIONS AND WARRANTIES OF BIOGEN

13.1     Compliance with Law. Biogen shall be responsible for testing Product
         and ensuring that Product complies, when shipped to Nova Factor, with
         all applicable laws, regulations, directives and requirements of the
         FDA, including without limitation, packaging and labeling requirements,
         product warning requirements, product design and safety requirements
         and advertising requirements.

13.2     Use of Trademarks. Biogen shall not use the trademark or tradenames of
         Nova Factor except to the extent necessary for activities contemplated
         under this Agreement.

13.3     Authority. Biogen represents that it has the authority to enter into
         this Agreement and that its execution of this Agreement and its
         performance of its obligations hereunder will not conflict with and is
         not prohibited by any other Agreement to which Biogen is a party.

13.4     Limitation on Liability. In no event shall Biogen be liable for loss of
         profit or any other incidental or consequential damages of Nova Factor.

14.      REGULATORY, INSPECTIONS, AUDITS

14.1     Information. Nova Factor shall provide to Biogen, at Biogen's request,
         any information reasonably required in connection with Biogen
         investigations relating to Services or any requests or investigations
         by or filings with governmental bodies, including the FDA or in support
         of Biogen's applications to the FDA. Nova Factor shall respond within
         two (2) business days to any reasonable requests for information by
         Biogen.

14.2     Audits, Inspections. Nova Factor shall from time to time submit to
         inquiries, audits and inspections by Biogen during normal business
         hours or at any other time during which the Services being audited are
         ongoing. Biogen shall give Nova Factor a least two (2) business days'
         prior notice of any audit or inspection and shall bear the costs of
         such audit or inspection.

15.      INDEMNIFICATION.

15.1     Biogen Indemnification of Nova Factor. Biogen shall at all times during
         the term of this Agreement and thereafter defend, indemnify and hold
         Nova Factor and its officers, directors, agents and employees harmless
         from and against any and all claims, suits, damages, liabilities, costs
         and expenses, including but not limited to court costs and reasonable
         attorneys' fees, incurred in connection with any third-party claim
         arising out of the use of any Product by an end-user, except to the
         extent caused by (i) the negligence or intentional misconduct of Nova
         Factor or any of its officers, directors, agents or

                                       15
<PAGE>   16

         employees or (ii) breach by Nova Factor of any of the terms of this
         Agreement or (iii) acts of Nova Factor or any of its officers,
         directors, agents or employees which are outside the scope of this
         Agreement.

15.2     Nova Factor Indemnification of Biogen. Nova Factor shall at all times
         during the term of this Agreement and thereafter defend, indemnify and
         hold Biogen and its officers, directors, agents and employees harmless
         from and against any and all claims, suits, damages, liabilities, costs
         and expenses, including but not limited to court costs and reasonable
         attorneys' fees, incurred in connection with any third-party claim
         arising out of (i) the negligence or intentional misconduct of Nova
         Factor or any of its officers, directors, agents or employees, (ii)
         breach by Nova Factor of any of the terms of this Agreement, or (iii)
         acts of Nova Factor or any of its officers, directors, agents or
         employees which are outside the scope of this Agreement.

15.3     Procedures. A party seeking indemnification under this Section shall
         give prompt notice of the claim to the other party and, provided that
         the indemnifying party is not contesting the indemnity obligation,
         shall permit the indemnifying party to control any litigation relating
         to such claim and disposition of any such claim, provided that the
         indemnifying party shall act reasonably and in good faith with respect
         to all matters relating to the settlement or disposition of any claim
         as the settlement or disposition relates to the parties being
         indemnified under this Section and the indemnifying party shall not
         settle or otherwise resolve any claim without prior notice to the
         indemnified party. The indemnified party shall cooperate with the
         indemnifying party in its defense of any claim for which
         indemnification is sought hereunder.

16.      CONFIDENTIALITY.

16.1     Nova Factor Obligation. Nova Factor agrees to treat any confidential or
         proprietary information obtained from Biogen and any confidential or
         proprietary information generated by Nova Factor in performing Services
         under this Agreement, including information regarding end-users,
         Biogen's pricing policies, information regarding reimbursement for the
         Product, information regarding the cost of providing services to Biogen
         and the information in the Database, and anything derived therefrom,
         (collectively, the "Biogen Information") as the confidential and
         exclusive property of Biogen, (except for the information in the
         Database which shall be joint property of Biogen and Nova Factor,
         subject to the limitations on Nova Factor's use of end-user lists as
         set forth in Section 12.12), and agrees not to disclose any of the
         Biogen Information to any third party without first obtaining the
         written consent of Biogen. Nova Factor agrees that it will use any
         Biogen Information only for purposes of performing its obligations
         hereunder and for no other purpose without the prior written consent of
         Biogen. Nova Factor further agrees to take all practicable steps to
         ensure that the Biogen Information will not be used by its directors,
         officers or employees, except on like terms of confidentiality as
         aforesaid, and will be kept confidential by them.

                                       16
<PAGE>   17

         The above provisions of confidentiality shall not apply to that part of
         the Biogen Information which Nova Factor is able to demonstrate by
         documentary evidence:

         (a)      was in Nova Factor's possession prior to receipt from Biogen;
                  or

         (b)      was in the public domain at the time of receipt from Biogen;
                  or

         (c)      became part of the public domain through no fault of Nova
                  Factor, its directors, officers or employees; or

         (d)      was lawfully received by Nova Factor from some third party not
                  disclosing the information on behalf of Biogen and having a
                  right of further disclosure; or

         (e)      is required by law to be disclosed, provided, however that
                  Nova Factor gives Biogen sufficient advance written notice to
                  permit Biogen to seek a protective order or other similar
                  order with respect to such Information.

         Nova Factor agrees that, at Biogen's request, it shall return to Biogen
         all parts of the Biogen Information existing in documentary form, not
         including pharmacy records, and will, at Biogen's request, return or
         destroy any copies thereof made by Nova Factor, its directors, officers
         or employees except that Nova Factor shall retain a copy of the
         Database, subject to the ongoing obligation of confidentiality. Nova
         Factor shall not dispose of the information in the Database without
         first offering in writing, given at least sixty (60) days prior to such
         disposal, to deliver the information to Biogen.

16.2     Biogen Obligation. Biogen agrees to treat any confidential or
         proprietary information obtained from Nova Factor, (not including the
         Database, information regarding end-users, and information about
         insurers' reimbursement policies with respect to Product) and anything
         derived therefrom, (collectively, the "Nova Factor Information") as the
         confidential and exclusive property of Nova Factor, and Biogen agrees
         not to disclose any of the Nova Factor Information to any third party
         without first obtaining the written consent of Nova Factor, provided
         that Biogen may disclose Nova Factor Information to any third party
         providing reimbursement-related services to Biogen as long as the third
         party is obligated to Nova Factor to keep such information
         confidential. Biogen agrees that it will use any Nova Factor
         Information only for purposes of activities contemplated hereunder and
         for no other purpose without the prior written consent of Nova Factor.
         Biogen further agrees to take all practicable steps to ensure that the
         Nova Factor Information will not be used by its directors, officers or
         employees, except on like terms of confidentiality as aforesaid, and
         will be kept confidential by them.

         The above provisions of confidentiality shall not apply to that part of
         the Nova Factor Information which Biogen is able to demonstrate by
         documentary evidence:

         (a)      was in Biogen's possession prior to receipt from Nova Factor;
                  or

                                       17
<PAGE>   18

         (b)      was in the public domain at the time of receipt from Nova
                  Factor; or

         (c)      became part of the public domain through no fault of Biogen,
                  its directors, officers or employees; or

         (d)      was lawfully received by Biogen from some third party not
                  disclosing the information on behalf of Nova Factor and having
                  a right of further disclosure; or

         (e)      is required by law to be disclosed, provided, however that
                  Biogen gives Nova Factor sufficient advance written notice to
                  permit Nova Factor to seek a protective order or other similar
                  order with respect to such Information.

         Biogen agrees that, at Nova Factor's request, it shall return to Nova
         Factor all parts of the Nova Factor Information existing in documentary
         form and will, at Nova Factor's request, return or destroy any copies
         thereof made by Biogen, its directors, officers or employees.

16.3     No Implied License. Nothing contained herein shall be deemed to grant
         to either party any rights or licenses under any patent applications or
         patents or to any know-how, technology, inventions or other
         intellectual property rights of the other party.

16.4     Publicity. Notwithstanding anything to the contrary contained in
         Section 12.3, Nova Factor shall be permitted to disclose to potential
         and existing customers of Nova Factor as well as to potential
         purchasers of stock or assets of Nova Factor or other potential sources
         of capital (i) that Nova Factor performs services and distributes
         Product under agreements with Biogen and (ii) the general nature of the
         relationship with Biogen. Nova Factor shall also be permitted to make
         such public statements regarding its relationship with Biogen as may be
         required by law, regulation or by obligations pursuant to any listing
         agreement with any securities exchange. Nova Factor shall not disclose
         the terms of this Agreement to any third party or, except as expressly
         set forth in this Section, make any public announcement of the
         existence of its relationship with Biogen without the prior written
         consent of Biogen except to its auditors and lawyers or as required by
         law.

16.5     Length of Obligation. The obligations of the parties under this Section
         17 shall continue during the term of this Agreement and for a period
         ending five (5) years after termination or expiration of this
         Agreement.

17.      INSURANCE.

         Nova Factor agrees (i) to obtain and maintain, while this Agreement is
         in effect, commercial general liability insurance, including product
         liability insurance, with coverage limits of not less than $1,000,000
         per occurrence and $3,000,000 in the aggregate, and (ii) not to cancel
         the insurance or reduce the coverage without giving at least thirty
         (30) days prior written notice to Biogen. Nova Factor shall cause
         Biogen to be a notice party on each insurance policy such that Biogen
         shall receive notice of any

                                       18
<PAGE>   19

         cancellation or change in the policy. At the request of Biogen, Nova
         Factor shall provide Biogen with a copy of a certificate of insurance
         to verify that insurance with the required coverage is in effect.

18.      TRAINING.

         Nova Factor shall be responsible for insuring that the personnel
         handling Product and Replacement Components, dealing with customers and
         payors and performing the Services contemplated under this Agreement
         are properly trained to perform their functions. Biogen and Nova Factor
         will use a jointly prepared training manual and orientation program for
         Nova Factor and Biogen personnel to familiarize the personnel with the
         Product, Services and the market.

19.      COMPETITIVE PRODUCTS

         As long as Nova Factor is providing Services under this Agreement, Nova
         Factor shall not perform services which are similar to the Services
         then being provided under this Agreement with respect to any products
         which compete with Product in the treatment of multiple sclerosis.

20.      MISCELLANEOUS

20.1     Binding; Assignment. This Agreement shall be binding upon and shall
         inure to the benefit of the parties hereto and their respective
         successors and assigns, provided that neither party shall have the
         right to assign this Agreement or its rights and obligations hereunder
         without the prior written consent of the other party, which such
         consent shall not be unreasonably withheld, except that Biogen may
         assign this Agreement or its rights and obligations hereunder to its
         Affiliates or successors in business who assume and agree to be bound
         by the terms hereof provided the entity has demonstrated financial
         ability to carry out Biogen's obligations hereunder.

20.2     Entire Agreement; Amendments. This Agreement and the Distribution
         Agreement constitute the entire and only agreement between the parties
         relating to the subject matter hereof, and all prior negotiations,
         representations, agreements and understandings are superseded hereby.
         No agreements amending, altering or supplementing the terms hereof may
         be made except by means of a written document signed by the duly
         authorized representatives of both parties.

20.3     Notices. Any notice required by this Agreement shall be given by
         prepaid, first class, certified mail, return receipt requested, or by
         air courier, hand delivery or facsimile, to the parties at the
         following addresses:

                                       19
<PAGE>   20

                  If to Biogen:

                           Biogen, Inc.
                           14 Cambridge Center
                           Cambridge, MA 02142
                           Attention: Vice President - Sales and Marketing
                           Fax: (617) 679-2333
                           with a copy to Vice President-General Counsel
                           Fax: (617) 679-2617

                  If to Nova Factor, Inc:

                           Nova Factor, Inc.
                           1620 Century Center Parkway
                           Suite 109
                           Memphis, TN 38134
                           Attention: President
                           Fax: (901) 385-3666

                           with a copy to: General Counsel

                           Thomas W. Bell, Jr.

                           Accredo Health, Incorporated
                           1640 Century Center Parkway
                           Suite 101
                           Memphis, Tennessee  38134
                           Fax: (901) 385-3689

         Any notice sent under this Section shall be deemed delivered within
         five (5) days if sent by mail and within twenty-four (24) hours if sent
         by fax, courier or hand delivery.

20.4     Force Majeure. Neither party shall be liable for any failure or delay
         caused by fires, flood, earthquakes, peril of the sea, accidents,
         explosions, sabotage, strikes, or other labor disturbances (regardless
         of the reasonableness of the demands of labor), civil commotions,
         riots, invasions, wars, acts, restraints, requisitions, regulations, or
         directions of governmental authorities, shortages of labor, fuel,
         power, or raw material, inability to obtain equipment or supplies,
         inability to obtain or delays in transportation, acts of God, or any
         other cause beyond its reasonable control.

                                       20
<PAGE>   21

20.5     Headings. Headings included herein are for convenience only, and shall
         not be used to construe this Agreement.

20.6     Independent Parties. For the purposes of this Agreement, the parties
         shall be, and shall be deemed to be, independent contractors and not
         agents or employees of the other party. No party shall have authority
         to make any statements, representations or commitments of any kind, or
         to take any action, which shall be binding on the other party, except
         as may be explicitly provided for herein or authorized in writing.

20.7     No Publicity. Except as required by law, neither party shall use the
         name of the other party or of any employee of the other party in
         connection with any publicity without the prior written approval of the
         other party.

20.8     Severability. If any provision of this Agreement shall be found by a
         court to be void, invalid or unenforceable, the same shall either be
         reformed to comply with applicable law or stricken if not so
         conformable, so as not to affect the validity or enforceability of this
         Agreement, except if the principal intent of the Agreement is
         frustrated by such reformation or deletion in which case this Agreement
         shall terminate.

20.9     No Deemed Waiver. Failure of either party to enforce a right under this
         Agreement shall not act as a waiver of that right or the ability to
         later assert that right relative to the particular situation involved
         or to terminate this Agreement as a result of any subsequent default or
         breach.

20.10    Governing Law. This Agreement shall be construed and enforced in
         accordance with the laws of the Commonwealth of Massachusetts.

20.11    Arbitration. Unless waived by the parties, any dispute, controversy or
         claim between the parties arising out of or relating to this Agreement
         either during or after the term hereof (including the question as to
         whether any particular matter is arbitrable) shall be solely and
         finally settled by arbitration conducted in Memphis, Tennessee, if the
         arbitration is initiated by Nova Factor or in the Boston, Massachusetts
         metropolitan area, if the arbitration is initiated by Biogen, in
         accordance with the Commercial Arbitration Rules of the American
         Arbitration Association then in force (the "Rules"). The party
         requesting arbitration shall serve upon the other party to the
         controversy, dispute or claim a written demand for arbitration stating
         the substance of the controversy, dispute or claim, the contention of
         the party requesting arbitration, and the name and address of the
         arbitrator appointed by it. The recipient of such demand shall within
         twenty (20) days after such receipt appoint an arbitrator and notify
         the party requesting arbitration of the identity of the arbitrator so
         selected, and the two arbitrators shall appoint a third, and the
         decision or award of any two arbitrators shall be final and binding
         upon the parties In the event that the two arbitrators fail to appoint
         a third arbitrator within twenty (20) days of the appointment of the
         second arbitrator, either arbitrator, or any party to the arbitration,
         may apply to a judge of the United States District Court for the
         district in which the arbitration is held for the appointment of the
         third arbitrator and the appointment of such arbitrator

                                       21
<PAGE>   22

         by such judge or such application shall have precisely the same force
         and effect as if such arbitrator had been appointed by the two
         arbitrators. If for any reason the third arbitrator cannot be appointed
         in the manner prescribed by the preceding sentence, either regularly
         appointed arbitrator, or either party to the arbitration, may apply to
         the American Arbitration Association for appointment of the third
         arbitrator in accordance with the Rules. If the parties upon whom the
         demand for arbitration has been served fail or refuse to appoint an
         arbitrator within twenty (20) days, the single arbitrator shall have
         the right to decide alone, and such arbitrator's decision or award
         shall be final and binding upon the parties. The decision of the
         arbitrator shall be in writing and shall set forth the basis therefor.
         The parties shall abide by all awards rendered in arbitration
         proceedings, and all such awards may be enforced and executed in any
         court having jurisdiction over the party against whom enforcement of
         such award is sought. The party losing the dispute which was submitted
         to arbitration shall pay the administrative charges, arbitrator's fees,
         and related expenses of arbitration, and each parties legal fees
         incurred in connection with any such arbitration. This agreement to
         arbitrate shall be specifically enforceable under the prevailing
         arbitration law.

         IN WITNESS WHEREOF, the parties have executed this Addendum on the date
first above written.

                                    BIOGEN, INC.

                                    By: /s/ Michael W. Bonney
                                        ----------------------------------------
                                        Michael W. Bonney
                                        Vice President - Sales and Marketing

                                    By: /s/ Darlene Romine
                                        ----------------------------------------
                                        Darlene Romine
                                        Director of National Accounts

                                    NOVA FACTOR, INC.

                                    By: /s/ David D. Stevens
                                        ----------------------------------------
                                    Title: Chairman

                                       22
<PAGE>   23

                                   SCHEDULE A

                              SERVICE FEE SCHEDULE

<TABLE>
<CAPTION>
             Activity                                                  Fee
             --------                                                  ---
<S>                                                                    <C>
Shipment of Replacements Components                                     *

Shipment of replacement Product to non-Nova Factor                      *
customers or shipment of Product to Investigators

Shipment of replacement Product to Nova Factor customers                *

Shipment of Product to Access Program Participants                      *

Shipment of Alliance Kits                                               *

Services related to Reimbursement Hotline and Hotline                   *
Customers

Outcome calls to Triaged Customers                                      *

Shipment of Product to Access Program Participants who                  *
require reimbursement services
</TABLE>

* - Confidential Treatment Requested

                                       23
<PAGE>   24

                                   SCHEDULE B

                                DATA AND REPORTS

                                       24
<PAGE>   25

                                   SCHEDULE C

                                        *

* - Confidential Treatment Requested

                                       25
<PAGE>   26

                                    Exhibit 1

                                        *

* - Confidential Treatment Requested

                                       26
<PAGE>   27

                                    Exhibit 2

                                        *

* - Confidential Treatment Requested

                                       27<PAGE>   1
                                                                    EXHIBIT 10.3

           AMENDED AND RESTATED CONTRACT FOR THE SALE AND DISTRIBUTION
                        OF GENENTECH HUMAN GROWTH HORMONE

This Amended and Restated Agreement is entered into effective April 8, 2000
("Effective Date'), by and between Genentech, Inc., a Delaware corporation with
offices at 1 DNA Way, South San Francisco, California 94080-4990 ("Genentech")
and Nova Factor, Inc., a Tennessee corporation with offices at 1620 Century
Center Parkway, Suite 109, Memphis, Tennessee 38134 ("Nova Factor"). Genentech
and Nova Factor are collectively referred to hereinafter as the "Parties" or
individually as a "Party".

WHEREAS, Genentech manufactures the recombinant human growth hormones
Protropin(R) (somatrem for injection), Nutropin(R) [somatropin (rDNA origin) for
injection], Nutropin AQ(R) [somatropin (rDNA origin) injection] and Nutropin(R)
Depot [somatropin (rDNA origin) for injectable suspension]; and

WHEREAS, the Parties entered into the Contract for the Sale and Distribution of
Genentech Human Growth Hormone effective March 1, 1997 ("1997 Agreement"), and
the Parties wish to amend the 1997 Agreement and restate their agreement
governing the sale of Genentech HGH (as defined below) to Nova Factor and the
distribution of such Genentech HGH by Nova Factor; and

WHEREAS, Nova Factor is a biotech contract pharmacy doing business throughout
the United States with respect to infusion care and human growth hormone
products;

NOW, THEREFORE, the Parties agree as follows:

1.  Definitions

    The following terms shall have the following meanings in this Agreement:

    (a) "Affiliate" shall mean any entity or person which controls, is
    controlled by or is under common control with a Party. For purposes of this
    definition, "control" shall mean (a) in the case of corporate or limited
    liability company entities, the direct or indirect ownership of at least
    thirty percent (30%) of the stock, participating shares or member interest
    entitled to vote; and (b) in the case of a partnership, the power
    customarily held by a general partner owning at least a 50% interest in the
    Partnership, and (c) in the case of a management contract the power to
    direct the management of the other entity. The foregoing notwithstanding,
    Roche Holding Ltd., a Swiss corporation, and its Affiliates (but
    specifically excluding Genentech and any entity owned or controlled by
    Genentech) shall not be considered Affiliates of Genentech for purposes of
    this Agreement. Nova Factor shall provide Genentech with a list of all
    current Affiliates, as defined below, beginning the Effective Date, which
    shall be attached hereto as Exhibit A. Such list shall include each
    Affiliate's name, address, class of trade, affiliation start date, type of
    affiliation with Nova Factor (e.g., subsidiary, joint venture, etc.), Health
    Industry Number ("HIN"), Drug Enforcement Agency Identification Number
    ("DEA"), and pharmacy department contact name, phone and fax number.

    (b) "Appeal(s)" shall mean any and all reasonable appeals to a decision of a
    third party payer to deny coverage for all or part of the pharmaceutical
    costs of Genentech HGH.

    (c) "Base Period" shall mean the six month period from October 1, 1999
    through March 31, 2000.

    (d) "Calendar Quarter" shall mean each full or partial calendar quarter
    period from January 1 through March 31, April 1 through June 30, July 1
    through September 30, October 1 through December 31 during the term of this
    Agreement.

    (e) "Calendar Year" shall mean each calendar year from January 1 through
    December 31 during the term of this Agreement.

    (f) "Competitive Unit" shall mean one milligram of Human Growth Hormone
    Product, as defined below, which is prescribed for treatment of any FDA
    approved indications for Genentech HGH.

* - Confidential Treatment Requested

                                       1
<PAGE>   2

    (g) "Contracted Customer" shall mean an entity with which Nova Factor
    contracts to provide contract pharmacy services with respect to growth
    hormone products to patients, or individuals enrolled as members, of such
    entity.

    (h) "Coverage Interruption" shall mean the date an insurance change or
    termination becomes effective, the date of therapy restart on a patient
    whose drug was therapeutically interrupted, or the date of determination of
    lack of medical necessity by a third party payer.

    (i) "Genentech HGH" shall mean those products listed in Exhibit B.

    (j) "Genentech HGH Base Market Share" shall mean * to patients * by the sum
    of (i) such total number of * to patients *, and (ii) the total number
    of * to patients for *.

    (k) "Genentech HGH Base Unit Volume" shall mean the total number of *.

    (l) "Genentech HGH Market Share" shall mean the total number of * divided by
    the sum of * and the *.

    (m) "Genentech HGH Unit" shall mean one milligram of Genentech HGH product.

    (n) "Genentech HGH Unit Volume" shall mean the total number of Genentech HGH
    Units Purchased by Nova Factor during each Calendar Quarter.

    (o) "Government Program" shall mean Medicaid, Medicare, Children's Medical
    Services or other governmental or similar program.

    (p) "Human Growth Hormone Product" shall mean any product (other than human
    growth hormone manufactured and sold by Genentech) that contains human
    growth hormone or an analog of human growth hormone, whether naturally
    occurring or manufactured by any process, which is prescribed for treatment
    of any FDA approved indications for Genentech HGH.

    (q) "Naive Competitive Patient" shall mean any patient who for the first
    time is prescribed and administered a Human Growth Hormone Product during
    the term of this Agreement.

    (r) "Naive Genentech HGH Patient" shall mean any patient who for the first
    time is prescribed and administered Genentech HGH during the term of this
    Agreement.

    (s) "Naive Genentech HGH Patient Base Market Share" shall mean the total
    number of *.

    (t) "Naive Genentech HGH Patient Market Share" shall mean the total number
    of *.

    (u) "National Genentech HGH Market Sales" shall mean the * during each *
    during each such * as determined by Genentech and subject to audit by Nova
    Factor pursuant to Section 13 below.

    (v) "National Nutropin Depot Market Sales" shall mean the total amount of *,
    as defined below, during each * during each such * as determined by
    Genentech and subject to audit by Nova Factor pursuant to Section 13 below.

    (w) "Nutropin Depot Unit" shall mean one milligram of Nutropin Depot.

    (x) For calculation purposes, "Dispensed" shall mean the transaction where a
    Genentech HGH product or Human Growth Hormone Product is taken out of Nova
    Factor's inventory and dispensed by Nova Factor to a patient, and
    "Purchased" and/or "Purchases" shall mean the transaction where a Genentech
    HGH product is ordered by and shipped to the purchasing entity.

2.  Sales of Genentech HGH By Nova Factor. Genentech hereby appoints Nova Factor
as a non-exclusive national distributor to sell Genentech HGH and to perform the
services set out herein and Nova Factor hereby accepts such appointment. All
sales of Genentech HGH by Nova Factor to patients shall be pursuant to a
physician's prescription, except that Nova Factor may sell Genentech HGH
directly to physicians' offices. Nova

* - Confidential Treatment Requested

                                       2
<PAGE>   3

Factor shall maintain the prescriptions for a period of at least four years or
as required by law, whichever is greater.

3.  Genentech HGH Discounts/Rebates.

    (a) Genentech HGH Discounts. The total "Discount" applicable to Genentech
    HGH Purchased by Nova Factor in each Calendar Quarter during each year of
    this Agreement shall equal the sum of the discount percentages described in
    this Section 3 and Exhibits C, D and E attached hereto.

        (1) Genentech HGH Base Discount.

            (a) Base Discount. Commencing on the Effective Date and for each
            Calendar Quarter throughout the term of this Agreement, Nova Factor
            shall receive a discount off the then-current list price for
            Genentech HGH in accordance with the discount schedule in Table 1 of
            Exhibit C attached hereto for the time period indicated ("Base
            Discount"). Genentech's published prices do not include applicable
            sales taxes.

            (b) Percent Decreases/Increases in Base Discount.

                (i) For each Calendar Quarter that the Genentech HGH Unit Volume
                    decreases by at *, the Base Discount shall be reduced by *.
                    In the event that the total Genentech HGH Unit Volume for
                    all Calendar Quarters combined in a Calendar Year decreases
                    by *, then the Base Discount shall be reduced by * for a *.
                    Genentech HGH Base Unit Volume and Genentech HGH Unit Volume
                    for each Calendar Quarter shall be determined by Genentech
                    pursuant to Genentech's records and subject to audit by Nova
                    Factor pursuant to Section 13 below. Within thirty (30)
                    calendar days from the end of each Calendar Quarter during
                    the term of the Agreement, Genentech shall provide to Nova
                    Factor a report showing aggregate Genentech HGH Base Unit
                    Volume and aggregate Genentech HGH Unit Volume for each such
                    Calendar Quarter.

               (ii) The Base Discount shall be reduced by an amount to be
                    mutually agreed upon in writing by Nova Factor and Genentech
                    for each Calendar Quarter that Genentech must pay a rebate
                    to a Contracted Customer on Genentech HGH Units Dispensed by
                    Nova Factor to patients, or individuals enrolled as members,
                    of such Contracted Customer.

              (iii) For each Calendar Quarter for which (i) Nova Factor
                    provides Genentech with the reports listed in Section
                    8(b)(1) and (d) and Exhibits H and J below, in accordance
                    with the terms of such Section 8(b)(1) and (d) and Exhibits
                    H and J, and (ii) Exhibit J provided by Nova Factor reflects
                    that Nova Factor offered the Nursing Services Program
                    described in Section 8(d) and Exhibit F below to * shall be
                    added to the Base Discount commencing on * ("Data
                    Discount"). For any Calendar Quarter for which Nova Factor
                    fails to provide all such reports to Genentech in accordance
                    with the terms of Section 8(b)(1) and (d) and Exhibits H and
                    J, or Exhibit J fails to reflect that Nova Factor offered
                    such Nursing Services Program to at least * of (i) such
                    reports in accordance with the terms of such Section 8(b)(1)
                    and (d) and Exhibits H and J, and (ii) an Exhibit J which
                    reflects that Nova Factor offered such Nursing Services
                    Program to * immediately prior to such receipt.

               (iv) In the event that Nova Factor provides the Financial
                    Hardship Program and the Nursing Services Program described
                    in Exhibit F below ("Programs") exclusively to patients who
                    are prescribed and administered Genentech HGH, * Genentech's
                    receipt of written evidence from Nova Factor of such
                    exclusivity ("Exclusivity Discount"). The Exclusivity
                    Discount shall remain in effect only so long as Nova Factor
                    continues to provide the Programs exclusively to patients
                    who are prescribed and administered Genentech HGH.

        (2) Purchase Discount. For each Calendar Quarter that Nova Factor's
        Purchases of Nutropin Depot Units as a percent of Nova Factor's total
        Purchases of Genentech HGH Units * set forth in Table 1 of Exhibit D
        attached hereto, the relevant additional discount amount set forth in
        Table 1 of Exhibit D shall be added to the sum of the Base Discount and
        any Data Discount and/or any Exclusivity Discount

* - Confidential Treatment Requested

                                       3
<PAGE>   4

        commencing on the * ("Purchase Discount"). For each Calendar Quarter
        that Nova Factor's Purchases of Nutropin Depot Units as a percent of
        Nova Factor's total Purchases of Genentech HGH Units *. In the event
        that Nova Factor's Purchases of Nutropin Depot Units as a percent of
        Nova Factor's total Purchases of Genentech HGH Units for all Calendar
        Quarters combined in a Calendar Year *. Nova Factor's Nutropin Depot
        Unit and Genentech HGH Unit Purchases for each Calendar Quarter and
        National Nutropin Depot Market Sales and National Genentech HGH Market
        Sales for each such Calendar Quarter shall be determined by Genentech
        pursuant to Genentech's records. Within thirty (30) calendar days from
        the end of each Calendar Quarter during the term of this Agreement,
        Genentech shall provide to Nova Factor a report showing (i) Nova
        Factor's total Purchases of Genentech HGH and Nutropin Depot for each
        such Calendar Quarter, and (ii) the total amount of National Genentech
        HGH Market Sales and National Nutropin Depot Market Sales for each such
        Calendar Quarter.

        (3) Naive Patient Genentech HGH Market Share Discount. For each Calendar
        Quarter that Naive Genentech HGH Patient Market Share is *, plus any
        Data Discount and/or any Exclusivity Discount, plus the relevant
        Purchase Discount achieved commencing * in Table 2 of Exhibit E, *
        ("Naive Genentech HGH Patient Market Share Discount"). For each Calendar
        Quarter that the Naive Genentech HGH Patient Market Share decreases by
        at least *, the Base Discount shall be reduced by *. In the event that
        the total Naive Genentech HGH Patient Market Share for all Calendar
        Quarters combined in a Calendar Year *, then the Base Discount shall be
        reduced by *.

        (4) Naive Genentech HGH Patient Market Share Exclusions. Erroneous data
        submitted to Genentech by Nova Factor shall not be included in the
        calculation of the Naive Genentech HGH Patient Market Share. Erroneous
        data shall include without limitation, duplicate Genentech HGH Units,
        Genentech HGH Units with invalid prescription numbers and aberrant
        Genentech HGH Unit amounts. Genentech shall provide written notice to
        Nova Factor of any suspected erroneous data within thirty (30) calendar
        days after Genentech's receipt of said erroneous data. Nova Factor shall
        have fifteen (15) calendar days to respond from the date of Nova
        Factor's receipt of such notice by providing Genentech with written
        evidence of the validity of said erroneous data. Evidence of validity
        shall include, but not be limited to, a physician prescription that does
        not include any patient names or identifiers that would breach patient
        confidentiality. In the event that Nova Factor fails to respond within
        fifteen (15) calendar days of receipt of such notice, then said
        erroneous data shall be excluded from the calculation of the Naive
        Genentech HGH Patient Market Share.

        (5) Affiliate Additions to and Deletions from the Discounts.

            (a) Additions to the Discount/Discount Calculation.

                (i) Additions to the Discount. For any entity that is added as
                    an Affiliate after the Effective Date of this Agreement
                    ("Affiliate Addition"), the *, provided that Genentech
                    receives notice of such Affiliate Addition from Nova Factor
                    at least fifteen (15) calendar days prior to the date upon
                    which such Affiliate Addition is added as an Affiliate and
                    such notice includes the information set forth in the notice
                    requirements described in Section 8(c) below. In the event
                    that Nova Factor fails to provide such notice to Genentech
                    at least fifteen (15) calendar days prior to the date on
                    which such Affiliate Addition is added as an Affiliate in
                    accordance with the notice requirements of such Section
                    8(c), *; provided that such notice includes the information
                    set forth in the notice requirements of Section 8(c).

               (ii) Additions to the Discount Calculation. The Genentech HGH
                    Units Purchased and/or Dispensed by Affiliate Additions to
                    Genentech HGH patients and/or Naive Genentech HGH Patients,
                    and Competitive Units Dispensed by such Affiliate Additions
                    to Naive Competitive Patients, for the Base Period and for
                    the Calendar Quarters following Genentech's receipt of
                    written notice from Nova Factor of such Affiliate Additions,
                    *; provided, however, that in order for Genentech HGH Units
                    Dispensed by such Affiliate Additions to Naive Genentech HGH
                    Patients and Competitive Units Dispensed by such Affiliate
                    Additions to Naive Competitive Patients *, Nova Factor must
                    provide to Genentech, at least two (2) calendar months prior
                    to the first day of such Calendar Quarter, (i) the Naive
                    Genentech HGH Patient Base Market Share report described in
                    Section 8(b)(2) and Exhibit I below for such Affiliate
                    Additions for the Base Period, and (ii) the Naive Genentech
                    HGH Patient Market Share report described in

* - Confidential Treatment Requested

                                       4
<PAGE>   5

                    such Section 8(b)(2) and Exhibit I for such Affiliate
                    Additions for the Calendar Quarter period that occurs two
                    Calendar Quarters prior to such Calendar Quarter. By way of
                    example, if Genentech receives written notice from Nova
                    Factor on August 5, 2000, that an entity is to be added as
                    an Affiliate, *, i.e., to be included in the calculation of
                    the Discount that commences on *, Nova Factor must submit to
                    Genentech, at least two (2) calendar months prior to *, (i)
                    the Naive Genentech HGH Patient Base Market Share report
                    described in Section 8(b)(2) and Exhibit I below for such
                    Affiliate Addition for the Base Period, and (ii) the Naive
                    Genentech HGH Patient Market Share report described in such
                    Section 8(b)(2) and Exhibit I below for such Affiliate
                    Addition for the Calendar Quarter *.

                (b) Deletions from the Discount/Discount Calculation. For any
                entities that are deleted as Affiliates after the Effective Date
                of this Agreement, the Genentech HGH Units Purchased by such
                Affiliates shall be excluded from the Discount *, which notice
                shall be provided in accordance with the notice requirements of
                Section 8(c) below. The Genentech HGH Units Purchased and/or
                Dispensed by such Affiliate deletions to Genentech HGH patients
                and/or Naive Genentech HGH Patients, and Competitive Units
                Dispensed by such Affiliate deletions to Naive Competitive
                Patients, for the Base Period and for the Calendar Quarters
                following Genentech's receipt of such notice, shall be excluded
                from the calculation of the Discount beginning the first day of
                the Calendar Quarter that * Genentech's receipt of such notice.

        (6) Services. In consideration for the Base Discount, Nova Factor shall
        offer all programs described in Exhibit F attached hereto to all
        patients to whom it dispenses Genentech HGH and to which the program is
        applicable.

    (b)Genentech HGH Rebate. For each Calendar Quarter that Nova Factor has a
    contractual arrangement with a Contracted Customer whereby Genentech HGH is
    the exclusive human growth hormone utilized or purchased by such Contracted
    Customer from Nova Factor, i.e., no other Human Growth Hormone Product is
    utilized or purchased by such Contracted Customer from Nova Factor,
    Genentech *, of such Contracted Customer within forty-five calendar (45)
    days after receipt of the report described in Section 8(b) and Exhibit G
    below.

4.  Orders and Returns. All purchase orders for Genentech HGH shall be submitted
by Nova Factor to Genentech in writing, by telephone, via facsimile or
electronic data interchange ("EDI") at least two (2) business days prior to the
requested date of shipment. The Discount applicable to such purchase order shall
be the Discount in effect upon the date such purchase order is accepted by
Genentech. No order will be binding upon Genentech until accepted by Genentech,
and Genentech shall have no liability to Nova Factor for purchase orders that
are not accepted. Nova Factor's purchase orders submitted to Genentech for
purchase of Genentech HGH shall be governed by the terms of this Agreement.
Nothing contained in any purchase order shall modify any terms herein stated or
add any terms or conditions not stated herein. All Genentech HGH delivered to
Nova Factor under this Agreement shall be suitably packed for air freight
shipment in Genentech's shipping cartons, marked for delivery to the address
provided by Nova Factor with the relevant purchase order, and shall be shipped
to Nova Factor, FOB Origin. Genentech shall ship Nutropin AQ to Nova Factor in
temperature controlled, validated, insulated shipping containers. Genentech HGH
shall be delivered to Nova Factor via second day air freight with shipping costs
prepaid by Genentech. Shipping charges for overnight delivery requested by Nova
Factor for Genentech HGH in excess of the standard shipping method chosen by
Genentech, shall be borne by Nova Factor. Genentech HGH Purchased by Nova Factor
shall be returned for credit only upon prior authorization by Genentech.
Genentech HGH returns in any Calendar Quarter * for the previous Calendar
Quarter. The Discount percentage applicable to such credit will be the Discount
in effect upon the date the returned Genentech HGH is received by Genentech.

5.  Nutropin AQ(R) and Nutropin Depot(TM) Shipping Requirements.

    (a) Nutropin AQ(R). Nova Factor shall ship Nutropin AQ(R) via Standard
    Overnight Service when external temperatures at any point in transit are
    between -5(Degree) to 37(Degree) Celsius (23(Degree) to 100(Degree)
    Fahrenheit), and via Priority Overnight Service with delivery by 10:30 a.m.
    the following day when external temperatures are greater or less than the
    foregoing parameters. Nova Factor shall ship, and shall require its agents
    to ship, Nutropin AQ(R) to customers in accordance with Genentech's
    validated shipping standards for Nutropin AQ.

* - Confidential Treatment Requested

                                       5
<PAGE>   6

    (b) Nutropin Depot(TM). Nova Factor shall ship, and shall require its agents
    to ship, Nutropin Depot(TM) to customers in accordance with Genentech's
    validated shipping standards for Nutropin Depot(TM).

6.  Payment to Genentech. Nova Factor shall pay Genentech in full, including
payment of applicable taxes, for Genentech HGH furnished to Nova Factor by
Genentech in accordance with the following payment terms:

    (a) From the Effective Date through *, Nova Factor's payment terms shall be
        * from the date of the invoice from Genentech; and
    (b) From *, through *, Nova Factor's payment terms shall be * from the date
        of the invoice from Genentech; and
    (c) From *, through the remaining term of this Agreement, Nova Factor's
        payment terms shall be * from the date of the invoice from Genentech.

     In the event that an Affiliate defaults in its payment to Genentech for any
     Genentech HGH Purchased by such Affiliate in accordance with the payment
     terms of this Section 6, Nova Factor shall be obligated to pay Genentech
     for such Genentech HGH Purchased by such Affiliate within ten (10) calendar
     days from the date of receipt of written notice from Genentech of such
     Affiliate's default. All payments will be made by check or wire transfer to
     Genentech's designated bank account on or before the morning of the due
     dates described in Section 6(a), (b) or (c) above, as applicable, and
     supporting documentation on the payment will be provided separately to
     Genentech. Genentech's designated account is as follows, subject to change
     by notice from Genentech:

     If by wire transfer:                   If by check:

                    Bank:  Mellon Bank             Bank:  Mellon Bank
                           Pittsburgh, PA                 Pittsburgh, PA

              ABA Number:  *                    Mail to:  Genentech, Inc.
            Account Name:  Genentech, Inc.                P.O. Box 360527
                        *  *                              Pittsburgh, PA 15251

7.  Product Availability; Responsibility for Expired, Damaged or Defective
Product. Genentech shall maintain a sufficient inventory of Genentech HGH
available to Nova Factor pharmacies to assure delivery thereof to a requesting
Nova Factor pharmacy by courier or mail within two (2) business days of
acceptance of a telephonic, EDI or written purchase order. In accordance with
Genentech's stated return of goods policy in effect at the relevant times,
Genentech shall reimburse or credit Nova Factor for any unused Genentech HGH
that is expired or defective, or that is damaged prior to or during shipment by
Genentech to a Nova Factor pharmacy, if it is returned to Genentech by Nova
Factor; provided that returns for each Calendar Quarter * by Nova Factor for the
previous Calendar Quarter. In the event of a product recall, Genentech shall
reimburse or credit Nova Factor for any unused Genentech HGH returned to
Genentech as a result of said recall, for the reasonable shipping costs and, for
the reasonable recall related administrative costs associated with said return.

8.  Nova Factor Reports and Audits.

    (a) Exclusive Genentech HGH Report. Within thirty (30) calendar days after
    the end of each Calendar Quarter, Nova Factor shall submit a report showing
    those Contracted Customers with which it has a contractual arrangement
    whereby Genentech HGH is the exclusive human growth hormone utilized by such
    Contracted Customer. Such report shall contain the identical data elements
    listed in Exhibit G attached hereto and shall be submitted on a 3.5" floppy
    disk in Microsoft Excel(TM) or text format to the address shown in the
    Exhibit G.

    (b) Market Share Reports.

        (1) Within thirty (30) calendar days after the Effective Date, Nova
        Factor shall provide Genentech with a Genentech HGH Base Market Share
        report by Nova Factor customer for all patients that were Dispensed
        Genentech HGH Units *. Thereafter, on or before the last day of the
        calendar month immediately

* - Confidential Treatment Requested

                                       6
<PAGE>   7

        following the last day of each Calendar Quarter, Nova Factor shall
        provide Genentech with a Genentech HGH Market Share report by Nova
        Factor customer for all patients that were Dispensed Genentech HGH Units
        *. Such reports shall contain the identical data elements listed in
        Exhibit H attached hereto, and shall be submitted on a 3.5" floppy disk
        in Microsoft Excel(TM) or text format to the address shown in Exhibit H.
        In addition, Nova Factor, with guidance and assistance from Genentech,
        shall develop and implement mutually agreeable market share programs to
        increase Genentech HGH Market Share. Along with the Calendar Quarter
        Genentech HGH Market Share report described in this Section 8(b)(1),
        Nova Factor shall also provide Genentech with a written update
        describing in detail any and all market share programs developed and
        implemented by Nova Factor throughout the term of this Agreement.
        Information concerning *.

        (2) Within thirty (30) calendar days after the Effective Date, Nova
        Factor shall provide Genentech with a Naive Genentech HGH Patient Base
        Market Share report by Nova Factor customer for all Naive Genentech HGH
        Patients that were Dispensed Genentech HGH Units for the Base Period and
        for all * that were * for the Base Period. Thereafter, on or before the
        last day of the calendar month immediately following the last day of
        each Calendar Quarter, Nova Factor shall provide Genentech with a Naive
        Genentech HGH Patient Market Share report by Nova Factor customer for
        all Naive Genentech HGH Patients that were Dispensed Genentech HGH
        Units, and for all Naive Competitive Patients that were *, for each such
        Calendar Quarter. Such reports shall contain the identical data elements
        listed in Exhibit I attached hereto, and shall be submitted on a 3.5"
        floppy disk in Microsoft Excel(TM) or text format to the address shown
        in the Exhibit I.

        (3) No patient specific data shall be provided by Nova Factor if such
        disclosure would violate any statute or regulation of any governmental
        entity.

    (c) Exhibit A Update Reports. Nova Factor shall provide Genentech with
    written notice of any entity to be added or deleted as an Affiliate under
    Exhibit A at least fifteen (15) calendar days prior to the date of such
    addition or deletion as an Affiliate. Additions to Exhibit A shall
    automatically be included as Affiliates under Exhibit A, unless Genentech
    notifies Nova Factor to the contrary within ten (10) calendar days after
    Genentech's receipt of such written notice. Genentech's approval of such
    additions shall not be unreasonably withheld. Such written notice from Nova
    Factor shall include the date upon which such entity is to be added or
    deleted as an Affiliate, as well as the entity's name, address, class of
    trade, HIN, DEA, type of affiliation with Nova Factor, and pharmacy
    department contact name, phone and fax number. For any addition, Nova Factor
    shall also provide a copy of such addition's applicable license. Nova Factor
    shall also provide Genentech with an updated Exhibit A, which includes all
    Nova Factor Affiliates, within thirty (30) calendar days from the end of
    each Calendar Quarter during this term of this Agreement. Such updated
    Exhibit A shall include the information set forth in this subsection(c) and
    shall be submitted on a 3.5" floppy disk in Microsoft Excel(TM) or text
    format. The information provided shall be submitted to Genentech, Managed
    Care Operations, Contract Administrator, 1 DNA Way, MS 13, South San
    Francisco, CA 94080 on a 3.5" floppy disk in excel or text format.

    (d) Nursing Services Program Report. Within thirty (30) calendar days from
    the Effective Date, Nova Factor shall develop the Nursing Services Program
    described in Exhibit F below. On or before the last day of the calendar
    month immediately following the last day of each Calendar Quarter, Nova
    Factor shall provide Genentech with a Nursing Services Program report, which
    shall contain the identical data elements listed in Exhibit J attached
    hereto, and shall be submitted on a 3.5" floppy disk in Microsoft Excel(TM)
    or text format to the address shown in the Exhibit J.

    (e) Nova Factor shall provide Genentech with a weekly and monthly report as
    follows:

        (1) The Nova Factor weekly and monthly reports shall utilize the
        parameters and information listed in Exhibit K attached hereto, and
        shall cover all patients for whom Nova Factor has received a
        prescription or purchase order for Genentech HGH in such week, all
        patients who have experienced a Coverage Interruption and an
        interruption in a patient's insurance or third party payer coverage for
        Genentech HGH due to a loss of employment or other event beyond the
        reasonable control of the patient or the patient's guardian; provided,
        however, that said reports shall not include patient names.

* - Confidential Treatment Requested
                                       7
<PAGE>   8

        (2) Reports will be centrally generated by Nova Factor and will contain
        transaction data from each of its distribution centers.

        (3) Reports will include any returns or negative transactions but will
        not include inter-distribution center transfers.

        (4) Nova Factor will retain sales transaction data for a four-year
        period or as required by law, whichever is greater.

        (5) The weekly sales reports shall be delivered to Genentech on the
        second business day following the end of each week and the monthly sales
        reports shall be sent to Genentech prior to the fifteenth (15th) day
        following the close of a calendar month.

        (6) The weekly and monthly sales report shall be reported in: (1) tape
        transfer using 8 mm. cassette tape or 9-track reel-to-reel tape in ASCII
        format, via overnight service, (2) hard copy, mailed, or (3) on-line
        modem transfer from Nova Factor to Genentech in ASCII format; provided
        however, that electronic formats only (formats (1) and (3) above) shall
        be provided commencing no later than April 1, 2000. Nova Factor in
        consultation with Genentech, will provide the hardware and software
        necessary to maintain and report the weekly and monthly sales
        transaction data described above. Written sales transaction reports
        should be sent to:

        Genentech, Inc.
        Attn:  Sales Administration
        1 DNA Way
        South San Francisco, CA 94080.

        (7) Upon reasonable request by Genentech, Nova Factor agrees to perform
        reconciliation's of sales reports to verify or correct the accuracy of
        the weekly and monthly reports.

        (8) Nova Factor shall maintain for a period of at least four (4) years
        all weekly and monthly reports and all correspondence with patients who
        are prescribed and administered Genentech HGH and their physicians and
        third party payers, including, without limitation copies of Statements
        of Medical Necessity, Explanations of Benefit, financial assistance
        applications and other Appeals correspondence. Nova Factor shall use its
        commercially reasonable best efforts to remedy all discrepancies
        identified by Genentech in its audits.

        (9) Genentech agrees to return computer tapes to Nova Factor within
        sixty (60) days of Genentech's receipt thereof.

    f. Performance Standards. Nova Factor shall monitor and keep records of the
    performance standards set forth in Exhibit L attached hereto. Nova Factor
    shall not be required to report to Genentech the data elements and status
    codes relating to such performance standards. Nova Factor shall be obligated
    to meet the "Standard" performance standard described in Exhibit L attached
    hereto. Any failure to meet such standard *. Nova Factor shall immediately
    notify Genentech of its failure to meet such performance standard at any
    time and its plan for correcting the default. Any such default shall be
    remedied within thirty (30) days of Nova Factor's notification of such
    default or Genentech's notification to Nova Factor that such default has
    occurred. Genentech shall have the right, during any audit, to audit the
    records of Nova Factor with respect to such performance standards.

9.  Nova Factor Services: Records; Handling; Control; Licensure. Nova Factor
shall:

    (a) in the event of a recall, supply Genentech with a complete record of
    accountability within one (1) business day of receiving Genentech's request
    for such record; and

    (c) store Genentech HGH at between 2(degree) and 8(degree) Celsius in a
    limited access refrigeration unit which will be locked during non-working
    hours and protected by a suitable alarm system, and dispense Genentech HGH

* - Confidential Treatment Requested

                                       8
<PAGE>   9

    with due regard for the need to guard against potential abuse or diversion;
    and

    (d) monitor refrigeration unit temperature by physically recording the
    temperature, at a minimum, twice each day or by utilizing a constant
    temperature recording device; and

    (e) maintain on a current basis all licenses and certifications as a
    registered pharmacy as required by applicable federal, state or local laws
    in all jurisdictions where Nova Factor delivers Genentech HGH; and

    (f) maintain in each branch involved in the distribution of Genentech HGH, a
    minimum Genentech HGH inventory level sufficient to meet two (2) weeks
    anticipated demand for that branch.

10. Distribution of Genentech HGH

    (a) Dispensing Obligation. In accordance with applicable laws and
    regulations, Nova Factor shall evaluate the reimbursement status of, and
    dispense Genentech HGH to, all patients with a prescription for Genentech
    HGH who are referred by any person or entity to Nova Factor. Within three
    (3) business days of Nova Factor's receipt of each prescription or other
    appropriate shipment request, Nova Factor shall dispense Genentech HGH to
    patients without regard to third party payer coverage of such patient's
    Genentech HGH; provided, however, that if the patient or physician
    specifically requests a delay in dispensing or if prior authorization is
    required for a Government Program patient, both as documented by written
    records of Nova Factor, said (3) day time frame shall not apply, and Nova
    Factor shall use its commercially reasonable best efforts to ship the
    requested Genentech HGH within thirty (30) days of such prescription or
    shipment request. Notwithstanding the preceding provisions, Nova Factor will
    not dispense Genentech HGH if the patient has drug on hand at the time of
    the referral. If prior authorization is required, regardless of whether
    payor is a government entity or not, Nova Factor *. As *, the criteria set
    forth above shall be deemed to have been met. Nova Factor shall also refer
    the *, mail order is less expensive for the patient, or if Nova Factor is an
    out of network provider.

    (b) Exceptions. Notwithstanding Section 10(a) above, Nova Factor shall not
    be obligated to dispense Genentech HGH to patients:

        (1) having no insurance or other third party payer coverage (or coverage
        equal to an amount less than fifty percent (50%) of Nova Factor's
        acquisition cost for Genentech HGH for such patient) for Genentech HGH
        after a duly diligent evaluation by Nova Factor of such patient's
        eligibility for all reasonable payer sources, including, without
        limitation, a Government Program; or

        (2) where the patient, physician or payer repeatedly and consistently
        refuses to assist with the reimbursement process, to complete the
        required documentation necessary to process the reimbursement request,
        or to process a request for coverage, as demonstrated by: (i) a failure
        to respond to at least three (3) consecutive Nova Factor contacts, at
        least one (1) of which is a written contact and all of which are
        documented in Nova Factor's written records; or (ii) a failure to
        substantially comply with the material requirements of a contract
        between the payer and the patient or physician; or (iii) a failure by
        the patient to pay Nova Factor within a reasonable time frame, Nova
        Factor agrees that it shall use its commercially reasonable best efforts
        to remedy the refusal, including, without limitation, contacting and
        cooperating with Genentech to resolve the issue with the patients, payer
        or provider, and exhausting all legal options under the federal, state,
        ERISA or other applicable reimbursement standards to resolve the
        coverage or claim request; provided, however, that the *, or *. In the
        event that such number of patients exceeds or threatens to exceed *
        beyond the reasonable control of the Parties, then the Parties shall
        meet to discuss methods to remedy such problems.

    c. Notice to Genentech. Promptly (which means Nova Factor shall use its
    commercially reasonable best efforts to notify within three (3) business
    days) after Nova Factor learns that a patient either lacks or is not
    eligible for any third party payer coverage for Genentech HGH, or at least
    fifteen (15) business days prior to Nova Factor terminating or electing not
    to ship to a patient during Appeals or due to a refusal to cooperate or
    otherwise, Nova Factor shall notify Genentech of such patient and the
    reasons for such patient's non-eligibility or lack of coverage, or for Nova
    Factor's refusal to service, as the case may be, and Genentech may provide
    Genentech HGH to such patient through its * or in any other manner Genentech
    chooses.

* - Confidential Treatment Requested

                                       9
<PAGE>   10

    d. Delivery Obligations. Nova Factor shall deliver Genentech HGH to the home
    of each patient or to such other delivery point as may be designated by the
    patient. Nova Factor may distribute Genentech HGH through its Affiliates
    and, with the prior written approval of Genentech, such approval not to be
    unreasonably withheld, to other third parties; provided, however, that Nova
    Factor hereby guarantees compliance by such Affiliates and third parties
    with the terms of this Agreement.

    e. Appeals and Collections. Nova Factor shall use its commercially
    reasonable efforts to obtain reimbursement from the patient and/or the third
    party payer or other payer, including in the event of a denial of insurance
    coverage, prosecuting all Appeals. Said Appeals shall include at least the
    following steps unless such step is not available: (a) obtaining a written
    denial of payment which sets forth the rationale for such denial; (b)
    sending a written appeal to the third party payer setting forth
    comprehensively the nature of the appeal and providing all relevant support
    for the appeal; and (c) sending a written appeal to the next higher level of
    appeal at that third party payer. As a general matter, Nova Factor shall
    ship on first level Appeals, and on second level Appeals when the clinical
    information of the patient falls within reasonable medical review criteria
    for treating growth hormone inadequacy. Nova Factor is not required to ship
    on patients with pre-existing clauses, lack of coverage for injectables, or
    no Rx coverage.

    f. Governmental Programs and UPP. For each patient who does not have third
    party payer coverage or for whom insurance coverage is in doubt, Nova Factor
    will promptly refer the patient * to assess that patient's eligibility for
    coverage of Genentech HGH under all appropriate Governmental Programs. Nova
    Factor shall use its best efforts to inform patients about meeting and, for
    patients with Governmental Program coverage, maintaining eligibility and
    coverage by Governmental Programs. If third party payer or Governmental
    Program coverage for Genentech HGH is not available, Nova Factor shall
    promptly contact such patient to determine the patient's ability to pay for
    the Genentech HGH with his or her individual funds. In the event that such
    patient is unable to pay for the Genentech HGH individually, Nova Factor
    shall promptly advise Genentech so that Genentech may consider the patient
    for Genentech's *.

    g. Patient Assistance Program. Nova Factor shall develop and administer a
    patient assistance program in accordance with applicable law and regulations
    to assist patients financially unable to afford Genentech HGH therapy;
    provided; however, that Nova Factor shall not have any obligation related to
    patients having no third party payer coverage for Genentech HGH therapy as
    described in Section 10(b)(1) which patients may be eligible for Genentech's
    *. Nova Factor shall develop its own financial criteria for patients and
    shall review each patient's financial status on a case-by-case basis, all in
    conformance with applicable laws, rules and regulations.

    h. Genentech Single Point of Contact. Genentech has developed a *
    reimbursement service program which is administered by Genentech or its
    subcontractor for patients with prescriptions for Genentech HGH *. Attached
    hereto as Exhibit M is a description of the *. Nova Factor shall be entitled
    to refer any patient for whom it has a prescription for Genentech HGH to
    such Program, provided that it complies with the requirements for
    distributors described in Exhibit M.

    i. Discontinuation of Provider Relationship. If at any time during the term
    of this Agreement, Nova Factor should discontinue acting as a Genentech HGH
    provider for a Nova Factor customer, then Nova Factor shall immediately
    notify Genentech and in any event shall provide Genentech with no less than
    sixty (60) business days prior written notice prior of such discontinuation
    of its Genentech HGH provider relationship with such Nova Factor customer.

11. Substitution and Counter-Detailing of Genentech HGH Products. Except as may
be required by applicable law, Nova Factor agrees that it shall not substitute,
generically or therapeutically, any other Human Growth Hormone Products for
prescriptions written for Genentech HGH, or any other Genentech HGH products for
prescriptions written for Nutropin Depot, to patients covered under this
Agreement, but specifically excluding patients who are covered under a
Government Program. Nova Factor and its Affiliates shall not counter-detail
Genentech HGH. * Nova Factor and its Affiliates agree not to (1) promote
against, counter-detail, or disparage the Genentech * system to be administered
by Genentech or its subcontractor for patients with prescriptions of Genentech
HGH, (2) promote against, counter-detail, or disparage the Genentech * operated
by * and implemented by Genentech for the distribution of Genentech HGH through
a network of pharmacies licensed to dispense Genentech HGH *, or (3) promote *.
Nova Factor may inform its customers of its status as an authorized dispensing
pharmacy within *; provided, however, that Nova Factor shall not so inform its
customers in

* - Confidential Treatment Requested

                                       10
<PAGE>   11

writing unless Genentech has previously approved, in writing, such written
materials, which approval shall not be unreasonably withheld. Nova Factor and
its Affiliates shall not convert or attempt to convert patients referred to Nova
Factor as a * provider to another delivery option. In the event that Genentech
elects to contract with an entity, other than * to operate *, Nova Factor
warrants and agrees that it shall cooperate with Genentech in transitioning
Genentech HGH patients to such entity. Nova Factor agrees that it shall make no
representation, guarantee or warranty about Genentech HGH, whether in writing or
orally, except as is contained in written materials delivered to Nova Factor by
Genentech for use in promoting and selling Genentech HGH or as may otherwise be
agreed to by Genentech in writing. Genentech shall have the right to approve
Nova Factor promotional materials which contain pertinent facts relative to
Genentech HGH and all such materials shall comply with applicable regulatory
requirements and shall not contain misrepresentations, either about Genentech
HGH or a competitive product, or disparage a competitive product.

12. Term; Termination.

    (a) Term. The term of this Agreement shall commence as of the Effective Date
    and shall remain in effect, unless terminated as provided below, until
    December 31, 2002, or until approval by the Food and Drug Administration of
    a new growth hormone product to be marketed and sold by Genentech, whichever
    occurs first. At least sixty (60) calendar days prior to the end of each
    year of this Agreement, the Parties shall conduct a business review to
    review and discuss the overall performance of this Agreement.

    (b) Termination Events. The foregoing notwithstanding, this Agreement may be
    terminated by a Party: (a) upon any material breach of this Agreement by the
    other Party which breach is not cured within sixty (60) days of written
    notice by the non-breaching Party; or (b) immediately upon giving notice (i)
    upon the institution by or against the other Party of insolvency,
    receivership or bankruptcy proceedings or any other proceedings for the
    settlement of the other Party's debts, (ii) upon the other Party's making an
    assignment for the benefit of its creditors, or (iii) upon the other Party's
    dissolution. This Agreement may also be terminated upon mutual agreement of
    the Parties hereto.

    (c) Effect of Termination. Upon termination, if requested by Genentech, Nova
    Factor shall return all unused Genentech HGH to Genentech and shall be
    reimbursed by Genentech for the reasonable shipping expenses of the return
    and the purchase price of the Genentech HGH returned if the purchase price
    was previously paid by Nova Factor. If Genentech does not request such
    unused Genentech HGH to be returned, Nova Factor may sell such unused
    Genentech HGH to patients or return it to Genentech for credit. Nova Factor
    shall also return, if so requested by Genentech, all sales aids and other
    associated material supplied to Nova Factor by Genentech. Termination shall
    not relieve either Party of obligations incurred prior to termination,
    including Nova Factor's obligation to pay for Genentech HGH ordered by and
    delivered to it under this Agreement, provided that Genentech has not
    requested return of that Genentech HGH. The provisions of Section 14(e) and
    (l) shall survive any termination of this Agreement.

    (d) Change In Control. If Nova Factor or any of its Affiliates or all or
    substantially all of either of their assets are to be acquired by whatever
    means, including merger within or into, another entity, including an
    Affiliate (the "Acquiring Entity"), Nova Factor shall so notify Genentech in
    writing at least sixty (60) business days prior to the date of occurrence of
    such event, and Genentech shall have the right to terminate this Agreement
    at any time until forty-five (45) business days after Genentech's receipt of
    written notice from Nova Factor. In addition, Genentech shall have the right
    to terminate this Agreement if Nova Factor or its Affiliates acquires all or
    substantially all of the assets of an entity or a division of any entity
    which in either case sold Genentech HGH within one year preceding such
    purchase. Nova Factor shall notify Genentech in writing at least sixty (60)
    business days prior to the occurrence of such event. If Genentech so
    terminates this Agreement, Nova Factor agrees for itself, its Affiliates and
    for any such entity that for a fourteen (14) month period (Restricted
    Period) thereafter it shall not switch Restricted Patients from a Genentech
    HGH product to a competitive Human Growth Hormone Product unless it receives
    a prescription from a physician specifically written for the competitive
    Human Growth Hormone Product. During the Restricted Period, Nova Factor
    further agrees that it shall not engage in any activities directed to payers
    or Restricted Patients or their physicians which are designed to switch
    Restricted Patients to a Human Growth Hormone Product which is competitive
    to Genentech HGH. During the Restricted Period, Nova Factor shall dispense
    Genentech HGH to Restricted Patients, except pursuant to any prescription
    specifically written for a Human Growth Hormone Product and comply with its
    reporting obligations hereunder and obligations under the terms of this
    Agreement in so far as the obligations relate to servicing the Restricted
    Patients during the Restricted Period. During the Restricted

* - Confidential Treatment Requested
                                       11
<PAGE>   12

    Period, Genentech agrees that to facilitate Nova Factor serving said
    patients, it shall sell Genentech HGH to Nova Factor at the then-current
    discount at the time of Agreement termination. For this purpose, "Restricted
    Patients" shall mean (i) those patients who on the date of the termination
    of this Agreement are then receiving Genentech HGH from Nova Factor, and
    (ii) new patients for whom Nova Factor receives a prescription for Genentech
    HGH or generic prescription. Notices hereunder shall not be required to be
    given if disclosure would cause Nova Factor or its Affiliates to be in
    violation of the federal or state securities laws and Genentech in any event
    agrees to keep such notices in strict confidence.

13. Audit. Either Party at its own expense may perform, or have an independent
third party auditor who has agreed to a confidentiality agreement reasonably
acceptable to the other Party perform, such audits as may be reasonably required
on a Party's business records and activities to ensure compliance with the terms
of the Agreement. Each Party shall provide the other Party with at least fifteen
(15) business days advance notice of such audits, and a Party shall cooperate
fully with the persons conducting the audit, including full access to the
necessary facilities and records at all reasonable times during business hours,
and copies, at such Party's expense, of all relevant records, provided; however,
that a Party's audit right shall be limited to bi-annual audits. Notwithstanding
the foregoing, Genentech shall also have the right to audit as Genentech may
deem necessary, in its reasonable judgment, to investigate quality assurance
problems that constitute material trends.

14. Miscellaneous.

    (a) Relationship. Neither Party is in any way the legal representative or
    agent of the other, nor authorized or empowered to assume any obligation of
    any kind, implied or expressed, on behalf of the other Party, without the
    express written consent of the other.

    (b) Force Majeure. Nonperformance of either Party, other than the payment of
    money, shall be excused to the extent that performance is rendered
    impossible by strike, fire, earthquake, flood, governmental acts or orders
    or restrictions, failure of suppliers, or any other reason where failure to
    perform is beyond the control and not caused by the negligence of the
    nonperforming Party.

    (c) Entire Agreement. This Agreement is the entire agreement between the
    Parties hereto, and supersedes any and all prior agreements between the
    Parties whether oral or written, relating to the subject matter hereof.
    Notwithstanding the foregoing, the Parties acknowledge the full and complete
    satisfaction of all obligations due to the other under that certain Contract
    For the Sale and Distribution of Genentech Human Growth Hormone, between
    Genentech and Nova Factor dated March 1, 1997. No amendments or
    modifications of the terms of the Agreement shall be binding on either Party
    unless reduced to writing and signed by both Parties.

    (d) Binding Effect. This Agreement shall be binding upon and inure to the
    benefit of the Parties hereto and their respective successors and assigns;
    provided, however, that this Agreement shall not be assignable by either
    Party without the other's written consent except to a wholly-owned
    subsidiary of such Party, the corporate parent of such Party, or a
    corporation controlled by the corporate parent of such Party.

    (e) Confidentiality. Nova Factor and Genentech shall take all reasonable
    steps and do all things reasonably necessary to ensure that any information
    relating to Genentech HGH, including the terms of this Agreement, the
    information relating to Genentech HGH provided in the Nova Factor weekly and
    monthly reports described in Section 8(e) and Exhibit K, or to the business
    of the disclosing Party ("Confidential Information") acquired by virtue of
    the position of the receiving Party under this Agreement, including, without
    limitation, information received through the exercise of a party's audit
    rights, shall not be disclosed or made use of outside this Agreement;
    provided, however, that the foregoing shall not apply to Confidential
    Information (a) which a receiving Party can show was known to it prior to
    disclosure by the disclosing Party; (b) which is or becomes public knowledge
    through no fault of the receiving Party; (c) which is lawfully disclosed to
    the receiving Party by a third party; (d) which is required to be disclosed
    pursuant to court order; or (e) which in the written opinion of legal
    counsel is required to be disclosed pursuant to federal or state law or
    regulation (including, without limitation, securities laws); provided that,
    in the case of (d) and (e) above, a reasonable opportunity is afforded the
    disclosing Party to challenge the requirement for such disclosure and/or
    request confidential treatment. Nova Factor shall be prohibited from
    providing or selling any data relating to Genentech HGH to a third party,
    except that Confidential Information specifically related to a third party
    payer's covered lives may

* - Confidential Treatment Requested

                                       12
<PAGE>   13

    be disclosed to such third party payer. This Section 14(e) shall survive any
    termination of this Agreement for a period of five (5) years from disclosure
    to the receiving Party.

    (f) Publicity. Nova Factor shall not originate any news release or public
    announcement, written or oral, to any person relating to this Agreement or
    to Genentech HGH except as previously agreed to by Genentech in writing and
    as in the written opinion of counsel to Nova Factor is required by law to be
    made. Except as required by law, Genentech shall seek approval from Nova
    Factor prior to utilizing Nova Factor's name in any written promotional
    material.

    (g) Waiver. Neither the waiver by either Party hereto of any breach of or
    default under any of the provisions of this Agreement, nor the failure of
    either Party to enforce any of the provisions of this Agreement or to
    exercise any right hereunder, shall be construed as a waiver of any
    subsequent breach or default, or as a waiver of any such rights or
    provisions hereunder.

    (h) Severability. If any part of this Agreement shall be invalid or
    unenforceable under applicable law, such part shall be ineffective to the
    extent of such invalidity or unenforceability only, without in any way
    affecting the remaining parts of this Agreement.

    (i) Governing Law. This Agreement shall be governed by and construed in
    accordance with the laws of the State of California. No provision of this
    Agreement shall be applied or construed in a manner inconsistent with
    applicable federal and state laws and regulations.

    (j) Enforceability. It is the explicit intention of the Parties hereto that
    no person or entity other than the Parties hereto, except governmental
    authorities to the extent required by law, is or shall be entitled to bring
    any action to enforce any provision of this Agreement against either of the
    Parties hereto.

    (k) Headings. The headings in this Agreement are intended solely for
    convenience of reference and shall be given no effect in the construction or
    interpretation of this Agreement.

    (l) Notices. Except as otherwise provided, all notices which may be required
    pursuant to this Agreement (a) shall be in writing, (b) shall be addressed,
    if to a Party, to the person and address set forth at the end of this
    Agreement (or to such other person or address as either Party may so
    designate from time to time), or addressed, if to a patient, to the
    patient's last known address, (c) shall be deemed to have been given three
    (3) business days from the date of postmark if sent by mail or on the date
    of delivery if transmitted by courier or telegram or on the date of
    transmission if sent by telex or facsimile, and (d) shall be mailed, postage
    prepaid, by first-class mail, registered mail, or certified mail, return
    receipt requested, or transmitted by courier for hand delivery, or by
    telegram, telex or facsimile with confirmation of transmission.

    (m) Limitation on Liability. If either Genentech or Nova Factor terminates
    this Agreement in accordance with the provisions of Section 12 above or if
    Genentech or any governmental agency effects the nationwide withdrawal of
    the sale of Genentech HGH for any reason, neither Party shall be liable to
    the other for any special, incidental or consequential damages caused
    directly or indirectly by such termination or withdrawal, whether arising
    under this Agreement or relating to any injury or damage to business,
    earnings, profits or goodwill suffered by that Party, including, without
    limitation any liability for compensation, reimbursement or damages on the
    account of the loss of prospective profits or anticipated sales or on
    account of expenditures, inventory, investments, leases or commitments in
    connection with the business or goodwill of either Party.

    (n) Affiliates. It is recognized and agreed that during the term of this
    Agreement, Nova Factor may distribute Genentech HGH to patients through its
    Affiliates and such distribution shall be construed as a distribution by
    Nova Factor and all provisions of this Agreement shall apply to such
    distribution and to the patients to whom Genentech HGH is distributed by
    Affiliates of Nova Factor.

    (o) Records. To the extent required by ss. 1861 (v)(1)(I) of the Social
    Security Act, 42 U.S.C. ss. 1395x(v)(1)(I), as amended, Genentech shall,
    upon proper written request, allow the United States Department of Health
    and Human Services, the Comptroller General of the United States and their
    duly authorized representatives, access to this Agreement and to books,
    documents and records necessary to verify the nature and extent of the costs
    incurred pursuant to this Agreement at any time during the term of this
    Agreement and for an additional period of four (4) years following the last
    date goods are furnished under this Agreement.

* - Confidential Treatment Requested

                                       13
<PAGE>   14

    (p) Compliance with Laws. Each Party shall be responsible for compliance
    with all state and federal laws, rules and regulations applicable to its
    performance hereunder, including, without limitation, those of the Food and
    Drug Administration and of Government Programs.

    (q) Government Disclosure and Reporting Obligations. Genentech shall inform
    Nova Factor of all Discounts and rebates payable hereunder to enable it to
    comply with its reporting and informational obligations pursuant to Section
    1128B(b) of the Social Security Act and 42 C.F.R. ss.1001.952, and all other
    similar or related federal and state laws and regulations. Genentech hereby
    informs Nova Factor that it must provide, upon request by the Secretary of
    Health and Human Services or a state agency, information relating to the
    Discounts and/or rebates provided by Genentech hereunder.

    (r) Counterparts. This Agreement may be executed in counterparts, including
    facsimile copies thereof, each of which shall be deemed an original, but all
    of which taken together shall constitute one and the same instrument.

    IN WITNESS WHEREOF, Genentech and Nova Factor have caused this Agreement to
be executed by their duly authorized representatives effective as of the day and
year first written above.

NOVA FACTOR, INC.                         GENENTECH, INC.

By: /s/ Randy Grow                        By: /s/ Kimberly J. Popovits
    ------------------------------            ----------------------------------
Name:  Randy Grow                         Name:  Kimberly J. Popovits

Title:  President                         Title:  Vice President, Sales

Date:  4/12/2000                          Date:  4/7/2000

Address:                                  Address:

1620 Century Center Parkway               1 DNA Way
Memphis, TN 38134                         So. San Francisco, CA 94080-4990
(901) 385-3633                            (650) 225-1000

Notices to be Addressed to:               Notices to be Addressed to:
President                                 Vice President - Sales

With a copy to:                           With a copy to:
Thomas W. Bell, Jr.                       Corporate Secretary
1640 Century Center Parkway
Suite 101
Memphis, Tennessee  38134
(901) 385-3680

* - Confidential Treatment Requested

                                       14
<PAGE>   15

                                    EXHIBITS

Exhibit A - Nova Factor Affiliates

Exhibit B - Genentech HGH Products

Exhibit C - *

Exhibit D - *

Exhibit E - *

Exhibit F - Base Discount Programs

Exhibit G - Exclusive Genentech HGH Dispensing Report

Exhibit H - Genentech HGH Market Share Report

Exhibit I - Naive Patient Genentech HGH Market Share Report

Exhibit J - Nursing Alliance Program Report

Exhibit K - Nova Factor Weekly Report

Exhibit L - Performance Standards

Exhibit M - *

* - Confidential Treatment Requested

<PAGE>   16

                                    EXHIBIT A

                             NOVA FACTOR AFFILIATES

Accredo Health, Incorporated
Hemophilia Health Services, Inc.
AHI Pharmacies, Inc.
Sunrise Health Management, Inc.
Southern Health Systems, Inc.

                                  PARTNERSHIPS

Texas Health Pharmaceutical Resources
Children's Home Care/Drug Therapies
Childrens Home Services
CM Factorcare
Childrens Biotech Pharmacy Services
Childrens Hemophilia Services

                            MANAGEMENT RELATIONSHIPS

LeBonheur Childrens Medical Center, Inc.
Alfred I. duPont Institute Children's Hospital
Dallas Childrens Medical Center
Cook Childrens Medical Center

* - Confidential Treatment Requested

<PAGE>   17

                                    EXHIBIT B

                                  GENENTECH HGH

          Protropin(R) (somatrem for injection)
          Nutropin(R) [somatropin (rDNA origin) for injection]
          Nutropin AQ(R) [somatropin (rDNA origin) injection]
          Nutropin Depot(TM)[somatropin (rDNA origin) for injectable suspension)

* - Confidential Treatment Requested
<PAGE>   18

                                    EXHIBIT C

*

* - Confidential Treatment Requested
<PAGE>   19

                                    EXHIBIT D

*

* - Confidential Treatment Requested
<PAGE>   20
                                    EXHIBIT E
*

* - Confidential Treatment Requested
<PAGE>   21

                                    EXHIBIT F

                             BASE DISCOUNT PROGRAMS

1.       THERAPY DATA
         Nova Factor provides weekly and monthly data to Genentech's Sales
Administration department. The data elements included in Exhibit K provide
Genentech with information to evaluate current and future activity by product,
physician, branch and patient identifiers. There reports include all patient
identifiers with any activity (new referral, active, on hold, discontinued,
Uninsured Patient Program or lost to the distributor).

2.       NATIONAL MEDICAID PHARMACY NETWORK
         Nova Factor maintains a national pharmacy network, providing service to
all states,except those listed on Exhibit F Schedule 1 which may be changed by
Nova Factor from time to time upon notice to Genentech.

3.       REIMBURSEMENT & ADMISSIONS
         *

4.       FINANCIAL HARDSHIP PROGRAM
         Nova Factor's Financial Hardship program (which is in no way promoted
or indicated as a service offering), is available for those patients who
demonstrate a need in meeting their co-payment obligations. Nova Factor shall
determine the patients' eligibility and work with the families to enroll them
into the program.

5.       VERIFICATION & SHIPMENT STANDARDS
         Nova Factor provides patients with high levels of care access and
responsiveness in accordance with the performance standards set forth in Exhibit
L below.

6.       COMPLIANCE & PERSISTENCY PROGRAM
         *

* - Confidential Treatment Requested

<PAGE>   22

7.       COMMUNICATION COMPLIANCE PROGRAM
         *

8.       CUSTOMER SATISFACTION DATA
         Customer satisfaction surveys & data analysis performed on an annual
basis.

9.       PATIENT EDUCATION & TRAINING
         Nova Factor shall provide comprehensive nursing services for ALL Naive
Patients and ongoing training as needed on Genentech's growth hormone products,
through Nova Factor's strategic Nursing Services Program. Specifically, services
consist of providing Injection site training for patients.

10.      NURSING SERVICES PROGRAM SURVEY
         *

11.      DAILY INVENTORY RECONCILIATION - LOT TRACKING
         Nova Factor's automated pharmacy system shall have the capability to
detect lot tracking in the event of product recall.

12.      ANCILLARIES SUPPLIES PROVIDED
         All ancillary hGH supplies shall at Nova Factor's discretion be
provided as part of Nova Factor's service to patients receiving Genentech HGH.
Nova Factor shall not at any time during the term of this Agreement provide
fewer ancillary hGH supplies to Genentech HGH patients than to other Human
Growth Hormone patients.

* - Confidential Treatment Requested
<PAGE>   23

                                    EXHIBIT F

                                   SCHEDULE I

                             STATES WITHOUT SERVICE

Connecticut
Washington, D.C.
Hawaii
Massachusetts
Maine
Nevada
Oregon
Rhode Island
Wisconsin
West Virginia

* - Confidential Treatment Requested
<PAGE>   24

                                    EXHIBIT G

                    EXCLUSIVE GENENTECH HGH DISPENSING REPORT

                                        *

* - Confidential Treatment Requested
<PAGE>   25

                                    EXHIBIT H

                       GENENTECH HGH MARKET SHARE REPORTBU

                                        *

                                Insert Exhibit H

* - Confidential Treatment Requested
<PAGE>   26

                                    EXHIBIT I

                 NAIVE GENENTECH HGH PATIENT MARKET SHARE REPORT

                                        *

* - Confidential Treatment Requested
<PAGE>   27

                                    EXHIBIT J

                                        *

* - Confidential Treatment Requested
<PAGE>   28

                                    EXHBIT K

                                        *

* - Confidential Treatment Requested
<PAGE>   29

                                    EXHIBIT L

                              PERFORMANCE STANDARDS

Nova Factor shall monitor data elements and status codes on all patients
receiving Genentech HGH. Performance will be monitored on all patients receiving
Genentech HGH except patients with diagnosis codes relating to infertility.
Patients receiving Genentech HGH through the * program shall have their first
shipment from Nova Factor measured as a maintenance shipment. Genentech's *
program shall notify Nova Factor at least seven (7) calendar days in advance of
the expected exhaust date of patients who have previously received a starter kit
and have chosen Nova Factor as the designated provider of service.

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------
     Performance           Optimal              Standard              Suboptimal          Failure to Meet
      Standard                                                                               Standard

-------------------------------------------------------------------------------------------------------------
<S>                   <C>                <C>                     <C>                   <C>
#1 Time to verify     At least 90%       80-89% within 72 hours  75-79% within 72      <75% within 72 hours
coverage              within 72 hours                            hours

-------------------------------------------------------------------------------------------------------------
#2 Time to Ship       At least 90%       80-89% within 72 hours  75-79% within 72      <75% within 72 hours
                      within 72 hrs. of  of referral date for    hours of referral     of referral date for
                      referral date for  initial shipment and    date for initial      initial shipment and
                      initial shipment   72 hours prior to       shipment and 72       72 hours prior to
                      and 72 hours       exhaust for             hours prior to        exhaust for
                      prior to exhaust   maintenance patients    exhaust for           maintenance patients
                      for maintenance                            maintenance patients
                      patients

-------------------------------------------------------------------------------------------------------------
</TABLE>

* - Confidential Treatment Requested
<PAGE>   30

                               EXHIBIT L (CONT.'D)

                      DESCRIPTION OF PERFORMANCE STANDARDS

*

* - Confidential Treatment Requested
<PAGE>   31

                               EXHIBIT L (CONT.'D)

ASSUMPTIONS/DEFINITIONS:

*

* - Confidential Treatment Requested
<PAGE>   32

                                    EXHIBIT M

                                        *

* - Confidential Treatment Requested
<PAGE>   33

                               EXHIBIT M (CONT.'D)

                                        *

* - Confidential Treatment Requested
<PAGE>   34

                               EXHIBIT M (CONT.'D)

                                        *

* - Confidential Treatment Requested
<PAGE>   35

                               EXHIBIT M (CONT.'D)

                                        *

* - Confidential Treatment Requested

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00009-of-00352.parquet"}]]